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1. Abstract 
Laminin B1 (LamB1) is a main component of the extracellular matrix and is involved in the 
regulation of tumor cell migration and invasion of during carcinogenesis. Metastasis of 
carcinoma cells is crucially linked to the process of epithelial to mesenchymal transition 
(EMT), which allows tumor cells to acquire a more motile phenotype and to dissociate from 
the epithelial cell cluster of the tumor. Expression profiling of polysome-associated mRNA 
revealed LamB1 to be translationally upregulated upon EMT of malignant hepatocytes. The 
enhanced translation of LamB1 in metastatic hepatocytes proved to be regulated by an 
internal ribosome entry site (IRES) located within the 5’-untranslated region (UTR) of the 
LamB1 transcript. IRES activity was detected by employing two independent reporter 
systems and verified by stringent assays for the presence of cryptic promoter or splice sites. 
The minimal cis-acting IRES sequence of 293 nucleotides that is required for cap-
independent translation was localized directly upstream of the start codon. Notably, the IRES 
trans-acting factor (ITAF) La was identified by RNA affinity purification as regulatory factor 
that interacts with LamB1 5’-UTR. This interaction was verified by RNA-immunoprecipitation 
in vivo, which revealed enhanced binding of La to the minimal IRES motif of LamB1 after 
EMT. Consistently, cytoplasmic levels of La were elevated in EMT-transformed cells and 
correlated with increased LamB1 protein expression. Furthermore, IRES-driven translation of 
LamB1 was elevated in the presence of La in vitro. Importantly, the EMT-induced 
cytoplasmic translocation of La was found to be triggered by platelet derived growth factor 
(PDGF) that is downstream of transforming growth factor (TGF)-β signaling. Together, these 
data demonstrate that La interacts with the LamB1 IRES in the cytoplasm, resulting in 
enhanced cap-independent translation of LamB1 in malignant hepatocytes that have 
undergone EMT. 
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2. Zusammenfassung 
Laminin B1 (LamB1) ist ein Bestandteil der extrazellulären Matrix und auf entscheidende 
Weise in der Regulation der Tumorzellmigration und –invasion während der Karzinogenese 
involviert. Ein essentieller Aspekt der Tumorprogression ist die Umwandlung epithelialer 
Tumorzellen zu einem mesenchymalen Phänotyp (EMT), der mit metastatischen 
Eigenschaften korreliert. Ein Expressionsprofil polysom-assozierter mRNA maligner 
Hepatozyten zeigte die Aktivierung der Translation von LamB1 in EMT-transformierten 
Zellen. Es stellte sich heraus, das die erhöhte Translation von LamB1 in metastasierenden 
Hepatozyten von einer internen Ribosomen-Bindungsstelle (IRES) reguliert wird, welche in 
der 5‘-untranslatierten Region (UTR) des LamB1 Transkripts lokalisiert ist. Zwei unabhängige 
bicistronische Reportersysteme wurden für die Bestimmung der IRES-Aktivität von LamB1 
verwendet. Zur Verifikation der IRES Aktivität wurde die Präsenz kryptischer Promotoren und 
Spleißstellen im 5’-UTR von LamB1 ausgeschlossen. Die minimale cis-agierende IRES 
Sequenz, welche für die „Cap“-unabhängige Translation notwendig ist, wurde mit einer 
Länge von 293 Nukleotiden direkt oberhalb des Startcodons lokalisiert. Mithilfe einer RNA 
Affinitätschromatography wurde der IRES trans-aktivierende Faktor (ITAF) La als 
Bindungspartner identifiziert, welcher mit der LamB1 5’-UTR in vitro interagiert. Diese 
Interaktion wurde durch eine RNA-Immunopräzipitation in vivo verifiziert. Weiters konnte die 
Bindung einer erhöhten Menge von La Protein an das minimale LamB1 IRES Motiv 
nachgewiesen werden. In Übereinstimmung mit dieser Beobachtung konnten erhöhte 
zytoplasmatische Mengen von La in EMT-transformierten Zellen detektiert werden. Überdies 
führte die Gegenwart von La zu einer gesteigerten IRES-meditierten Translation von LamB1 
in vitro. Platelet derived growth factor (PDGF) wurde als auslösender 
Signaltransduktionsweg für die zytoplasmatische Translokation von La identifiziert. 
Zusammenfassend konnte damit nachgewiesen werden, dass der PDGF Signalweg für die 
zytoplasmatische Akkumulation von La und damit der Interaktion mit dem LamB1 IRES 
verantwortlich ist, wodurch die cap-unabhängige Translation von LamB1 in malignen 
Hepatozyten nach EMT aktiviert wird. 
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3. Introduction 
3.1. Tumorigenesis of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the third most common cause for cancer related mortality 
worldwide [1]. The vast majority of HCC develop as a consequence of chronic inflammatory 
liver disease and are preceded by liver fibrosis and cirrhosis [2]. Infection with hepatitis B and 
C virus is believed to be the main etiologic factor in over 80% of cases [3]. Other etiologies of 
HCC include dietary risk factors such as exposure to aflatoxin or chronic alcohol intoxication 
as well as hereditary hemochromatosis and non-alcoholic fatty liver disorders [3]. Reports 
demonstrate that the worldwide incidence of HCC increased in recent years [4]. Limited 
therapeutic options and late diagnosis due to the asymptomatic nature of early disease 
stages are the main reasons for the high mortality rate in patients with HCC [5]. Partial 
hepatectomy and orthotopic liver transplantation are considered the only effective treatments 
of HCC [6]. The option of partial hepatic resection is restricted to patients at an early disease 
stage with preserved liver function and resectable tumors [6]. Even after successful surgery 
the rate of tumor recurrence is high due to intrahepatic metastasis [7]. The development of 
new therapeutic approaches requires improved knowledge of tumorigenic processes and the 
signaling pathways that regulate relevant mechanisms such as tumor cell proliferation, 
angiogenesis, invasion and metastasis. 
Angiogenesis and tumor vascularization 
Intrahepatic metastasis critically depends on the ability of tumor cells to acquire migratory 
and invasive properties as well as on angiogenesis. The liver is a highly vascularized organ 
with an extraordinary regenerative potential [8]. Proliferative regeneration of hepatocytes in 
response to intoxication requires efficient neovascularization [9]. Angiogenesis relies on the 
recruitment and activation of pericytes and vascular endothelial cells [10]. The angiogenic 
process is induced by HIF1α in response to hypoxia, resulting in secretion of angiogenic 
factors including vascular endothelial growth factor (VEGF)-A, angiopoitin-2 and platelet 
derived growth factor (PDGF), which have been shown to be upregulated in HCC patients 
compared with cirrhotic patients [11]. These growth factors orchestrate the angiogenic switch 
in autocrine and paracrine signaling loops between endothelial cells, pericytes and tumor 
cells [12]. Neovascularization starts with destabilization of the existing vasculature leading to 
a high vascular permeability, which is thought to promote tumor metastasis [13]. 
Remodulation of the extracellular matrix (ECM) plays an important regulatory role throughout 
the whole angiogenic process (Figure 1). Endothelial cells are quiescent under normal 
conditions when they are bound to the capillary basement membrane [14]. Degradation of 
the basement membrane by metalloproteinases (MMPs) allows endothelial cells to dislodge 
from the existing vasculature and sequestered growth factors such as VEGF and basic 
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fibroblast growth factor (bFGF) are released [13]. When the basement membrane is 
disassembled the endothelial cells may interact with different domains of the same set of 
proteins [15]. This concept of regulation means that ECM signaling depends not only on 
composition but also on the structural configuration of the matrix. The provisional ECM 
regulates migration and proliferation of activated endothelial cells [16]. In tumors the ECM 
conformation reassembles the provisional matrix and therefore constantly stimulates the 
endothelial cells [16, 17]. As angiogenesis precedes changes in composition and 
arrangement of the ECM induce endothelial sprouting and tube formation. 
 
Figure 1: VEGF, PDGF and bFGF signaling coordinates the angiogenic process between peri-
cytes, endothelial cells and tumor cells. The vascular basement membrane (VBM) is degraded by 
MMP into a provisional matrix. Growth factors are released from the provisional matrix or secreted by 
tumor and tumor stroma cells, leading to the generation of an intermediate matrix and the subsequent 
mature basement membrane [15].  
Tumor cell dedifferentiation and metastasis 
HCC arises from epithelial hepatocytes, which are highly differentiated cells with specialized 
metabolic function [8]. Dedifferentiation of malignant hepatocytes and dissemination from the 
primary tumor is a pivotal step towards vascular invasion and intrahepatic metastasis and 
therefore a central event in the pathogenesis of HCC. The underlying process, referred to as 
epithelial to mesenchymal transition (EMT), is characterized by loss of epithelial cell polarity 
and acquisition of a fibroblastoid phenotype that enables tumor cells to leave the epithelial 
cell cluster (Figure 2) [18-20]. Epithelial cells are arranged in monolayered sheets, in which 
cells exhibit a apical basolateral polarity [21]. While the apical side faces the lumen, the 
lateral side associates with the basement membrane. Collagen and laminins are the main 
ECM components of the basement membrane that bind lateral integrin receptors of the cell 
[15]. The integrin transmembrane receptors contain an extracellular domain that interacts 
with the ECM and an intracellular domain that is connected to the actin cytoskeleton. 
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Integrins therefore link the cellular cytoskeleton to the ECM and maintain the structural 
stability and polarity of the cell [22]. Furthermore,  the cells are connected with each other by 
tight junctions, adherence junctions and desmosomes [19]. E-cadherin forms an intercellular 
belt of adhesion junctions through homotypic interaction of the extracellular domain that is 
characteristic for epithelial cells. The intercellular domain is connected through β- and α-
catenin with actin filaments [23]. Loss of E-cadherin junctions, as well as tight junctions that 
are provided by occluding and claudins are central features of EMT [24]. Dissolution of cell-
cell junctions leads to cytoskeletal rearrangements of the associated actin filaments into 
stress fibres and expression of the mesenchymal cytoskeletal protein vimentin resulting in a 
motile fibroblastoid phenotype. Detachment of cells from one another causes cell 
depolarization and changes of integrin receptor distribution and expression, facilitating cell 
motility and survival [22]. Concurrently with the attenuation of epithelial traits the cells 
undergoing EMT acquire a mesenchymal expression profile. Mesenchymal cell 
characteristics include an increased deposition of ECM components such as collagens, 
laminins and fibronection which promote cell migration through integrin mediated focal 
adhesion complex formation. Enhanced secretion of MMPs of EMT transformed cells 
facilitates matrix degradation and allows cell invasion [25].  
 
Figure 2: Epithelial to mesenchymal transition. Transition of epithelial to mesenchymal cells is 
characterized by the dissolution of cell-cell adherence junctions (blue), thigh junctions (black) and 
desmosomes (green). Cells loose the apical-basolateral polarity and aquire a mesenchymal pheno-
type by reorganisation of the actin cytoskeleton into stress fibres (red) [19]. 
EMT is a physiological event that takes place during gastrulation when epithelial cell sheets 
convert into mesenchymal cells to migrate and form the embryo and it is also involved in 
organogenesis [26]. EMT contributes to fibrotic, non-regenerative wound repair in the lung, 
kidneys and liver. It was shown that approximately 10% of fibroblasts in a fibrotic liver derive 
from hepatocytes via EMT [27]. However recent data contradict these findings leading to a 
controversal discussion wheter hepatic epithelial cell contribute to liver fibrosis [28]. 
Hepatocellular EMT is induced by the cooperation of TGF-β with active H-Ras signaling [29]. 
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Ocogenic activation of Ras as well as enhanced secretion of TGF-β and establishment of 
autocrine TGF-β signaling loops are frequently observed in HCC patients and correlate with 
increased tumor aggressiveness and metastasis [30-33]. TGF-β signals through a complex 
of type I and type II serine threonine kinase receptors [34]. Type II phosphorylates the type I 
receptor, which in turn activates the associated transcription co-factors Smad2 and Smad3 
by C-terminal phosphorylation. The activated Smads 2 and 3 are joined by Smad 4 and the 
Smad trimer then translocates into the nucleus where it regulates gene transcription. The 
Smad induced transcription response is mainly driven by three families of transcription 
factors including the Snail, ZEB and cHLH (Twist) family [35]. These transcription factors 
orchestrate the downregulation of epithelial genes such as proteins that comprise epithelial 
cell-cell junctions and activate the expression of mesenchymal genes including cytoskeletal 
proteins, ECM components and MMPs [36]. Besides carnonical Smad signaling, TGF-β also 
elicits Ras activated Erk MAP kinases, Rho GTPases and the PI3 kinase/Akt pathway [37]. 
These Smad independent pathways are important effectors that regulate cytoskeleton 
reorganization, cell growth and survival. TGF-β plays a dual role in tumor progression. In 
normal liver cells it acts as a tumor suppressor by inducing cell cycle arrest and apoptosis, 
whereas in malignant cells it controls EMT and dedifferentiation. The tumor promoting effect 
of TGF-β depends on the aberrant activation of oncogenic pathways that promote EMT and 
counteract the cytostatic cell response. Hyperactive Ras and downstream MAPK signaling is 
required for TGF-β mediated EMT [38]. MAPK signaling ehhances the TGF-β induced 
downregulation of E-cadherin and induction of matrix metalloproteinase expression [39, 40]. 
ERK kinases phosphorylate the linker region of receptor Smads and thereby modulate the 
TGF-ß induced canonical signaling [41]. Focal adhesion kinase (FAK) dependent activation 
of PI3K signaling on the other hand protects from TGF-β induced apoptosis [42, 43]. Studies 
of EMT kinetics in murine HCC models revealed the induction of EMT depends on MAPK 
signaling, whereas additional activation of PI3K signaling at a later time point is required for 
the maintenance of EMT [44]. The PI3 kinase mediated maintenance of EMT was found to 
depend on PDGF signaling [45]. Both PDGF receptors α and β were shown to be expressed 
upon EMT and PI3K signaling was driven by an autocrine loop of PDGF-A [46]. TGF-β and 
downstream PDGF signaling loops are regulated by autocrine secretion of malignant 
hepatocytes as well as by paracrine activation from myofibroblasts of the tumor stroma. 
Furthermore, PDGF signaling is essentially involved in regulating the nuclear accumulation of 
β-catenin [46]. In epithelial cells β-catenin is attached to the intracellular domain of the E-
cadherin and links the adherence junctions to the cytoskeleton. Degradation of E-cadherin 
during EMT releases β-catenin into the cytoplasm. In absence of Wnt signaling cytoplasmic 
β-catenin is phosphorylated by GSK-β and marked for degradation. Active Wnt signaling 
inhibits GSK-3ß and allows the nuclear translocation of β-catenin and subsequent induction 
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of EMT target gene expression [12, 47]. The role of PDGF in β-catenin signaling remains to 
be clarified but interference with PDGF abolishes the nuclear accumulation of β-catenin [46]. 
Importantly, nuclear localization of β-catenin correlates with dedifferentiation of malignant 
hepatocytes to hepatocyte progenitors [48]. This data supports the connection between EMT 
induced dedifferentiation and the origin of tumor stem cells [18].  
3.2. The role of Laminin B1 in tumorigenesis  
Interaction of tumor cells with the ECM affects differentiation, angiogenesis, migration and 
cell differentiation and therefore plays an important role in tumorigenesis [15]. Laminins are 
the main non-collagenous component of the ECM. They assemble the basement membrane 
via formation of polymers and the nidogen mediated interaction with type IV collagen [49]. 
The heterotrimeric laminin glycoproteins are composed of several α-, β- and γ-subunits that 
give raise to fifthteen different laminin isoforms which are expressed in a tissue specific 
manner (Figure 3) [50, 51]. Six laminin isoforms contain laminin B1 (LamB1) as β-subunit, 
such as laminin 1 that is expressed in some adult epithelium including the liver and the 
laminin isoforms 8 and 10 that are expressed by endothelial cells [49]. 
 
Figure 3: Composition of the heterotrimeric laminin isoforms. Diverse α-, ß- and γ- subunits 
compose fifthteen different heterotrimeric laminin isoforms [50] 
LamB1 mediated signaling  
Laminin signaling is implemented by heterodimeric integrins, α-dystroglycan, syndecans and 
the monomeric laminin receptor (LamR) [52, 53]. All of these receptors or coreceptors 
regulate signaling cascades that are essentially involved in tumorigenesis [54]. α-
dystroglycan is thought to modulate Ras mediated MAPK signaling via interaction with 
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growth factor receptor-bound protein (Grb) 2 [55, 56]. Syndecans act as coreceptor and 
modulate signaling of a large variety of ligands such as VEGF, FGF and TGF-β [57-59]. The 
laminin isoforms that contain laminin B1 activate α1β1, α2β1, α3β1, α6β1, α7β1, α9β1and 
α6β4 integrin receptors [60]. Aberrant activation of integrin signaling is a frequent event 
during tumorigenesis and is involved in the regulation of tumor cell mitosis, migration, and 
proliferation and survival [61, 62]. Major integrin triggered signaling cascades that regulate 
cell motility include Ras/ERK, Src-like kinase/Cdc42, FAK/Rac-1and the RhoA pathway [61, 
63]. Integrins enhance expression and activation of MMPs that facilitate cell migration by 
catalyzing ECM degradation. Interestingly, cell detachment from the ECM results in loss of 
integrin promoted, PI3K-, ILK-, ERK-, and JNK- mediated survival signals, leading to anoikis 
[64, 65]. Furthermore, cell proliferation essentially requires the combined activation of 
integrin and growth factor receptor mediated ERK signaling [66, 67]. 
The 67kDa LamR is specifically activated by interaction with LamB1 [53]. Overexpression of 
LamR is a frequent event in diverse carcinoma and correlates with enhanced metastatic 
potential and poor patient survival [68]. LamR drives laminin induced tumor cell attachment 
[69-71], tumor cell migration [72], invasion and agiogenesis [73] and was recently shown to 
be vital for tumor proliferation and survival [74]. Interestingly LamR was found to physically 
interact with α6ß4 integrin that is associated with carcinoma progression by contributing to 
apoptosis resistance, invasion and metastasis [75]. Furthermore LamR is able to remodel the 
structure of laminin-1 resulting in altered gene expression and increased tumor 
aggressiveness [76]. 
LamB1 in tumorigenesis  
Tumor progression is characterized by deregulation of ECM-cell interactions through 
changes in laminin expression or their associated receptors [77]. Tumor neovascularisation, 
invasion and metastasis primarily depend on aberrant ECM-cell interactions [78]. For 
example, an angiogenic switch from laminin 9 and 11 to the LamB1 composing laminin 8 and 
10 occurs in breast carcinomas [79]. Laminin 8 and 10 was found in vessel walls of 
carcinomas and their metastasis but not in normal tissue. Interestingly, expression of those 
laminins increased in a tumor progression dependent manner. Accordingly, LamB1 peptides 
were shown to stimulate endothelial cell adhesion, tube formation and sprouting [80]. An 
increasing number of studies implicate that LamB1 is essentially involved in the angiogenic 
process by stimulating the differentiation and vascular tube formation of endothelial cells. 
LamB1 peptides as well as laminin 1 were found to promote angiogenesis [81, 82]. 
Furthermore, laminin 1 was shown to enhance the metastatic potential of tumor cells by 
promoting tumor cell migration and proteinase secretion [72]. Carcinoma in situ are 
separated from surrounding tissue compartments by the basement membrane. Degradation 
and remodulation of the existing basement membrane by invading tumor cells is a 
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prerequisite for metastasis [83]. Dedifferentiated tumor cells as well as tumor stroma 
myofibroblasts secrete extracellular components and form their own matrix [83]. Tumor cell 
migration is regulated by the interplay of the remodulated ECM and changes in intergrin 
receptor expression. Acquisition of an invasive cell phenotype by EMT depends on the 
cooperation of integrin activated FAK signaling with receptor tyrosine kinase signaling, which 
together regulate Rac mediated restructuring of the cytoskeleton [54].  Besides its central 
role in tumor cell migration and metastasis, EMT mediated dedifferentiation is supposed to 
contribute to the acquisition of tumor stem cell traits [18]. Accordingly, integrins were found to 
drive self renewal and differentiation of stem cells [18, 84]. Thus the laminin composition of 
the ECM may also be involved in the regulation of stem cell differentiation. Laminin mediated 
ß1 integrin signaling in neuronal stem cell niches for example is required to maintain the 
stem cell phenotype [85]. Recently it was shown that human embryonic stem cells can be 
cultivated on laminin 10 without feeder cells or supplementation of any additional proteins 
[86]. Laminin isoforms therefore could also play a role in tumor cell dedifferentiation and 
formation of tumor stem cells. 
LamB1 in HCC 
Overexpression of LamB1 has been reported particularly in the context of HCC. Cirrhosis 
that frequently precedes HCC is characterized by increased ECM deposition as a result of 
chronic liver injury and scar formation [2, 4]. In transgenic mice, LamB1 expression was 
induced during transforming growth factor (TGF)-β driven liver fibrosis [87]. Proteome 
analysis of HCC patients revealed a rise in LamB1 levels in cirrhotic tissue compared with 
normal tissue and levels further significantly increase in carcinomas [88]. The elevation of 
LamB1 expression in HCC goes along with altered expression of beta1 integrins as well as 
LamR upregulation [89]. The combined deregulation of LamB1 and associated receptor 
expression in HCC affects multiple processes that are relevant for tumorigenesis, such as 
tumor cell survival, neovascularisation and migration.  
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3.3. Mechanisms of translation initiation 
Translation initiation by ribosome scanning 
Translation describes the production of proteins from mRNA matrices. The multistep process 
of translation is divided into initiation, elongation, termination and ribosome recycling [90, 91]. 
During translation initiation the AUG start codon is identified by a preinitiation complex and 
decoding of the open reading frame starts with a methionyl tRNA (Met tRNAi) that is 
specialized to read the initiation codon. Canonical initiation factors mediate the recruitment of 
the ribosomal subunits to the mRNA in order to form the preinitiation complex. At the start 
codon the preinitiation complex is joined by the 60S ribosomal subunit to generate the 80S 
ribosomal complex that drives protein synthesis. 
 
Figure 4: Translation initiation by cap dependent ribosome scanning [92]. 
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Translation of the majority of transcripts is initiated by a mechanism referred to as ribosome 
scanning [92]. The preinitiation complex scans the untranslated region (UTR) until a suitable 
start codon is identified (Figure 4). This process starts with the recognition of the cap 
structure at the 5’ terminus of the mRNA by eukaryotic initiation factor (eIF) 4E. eIF4E is part 
of the initiation factor complex eIF4F that also comprises eIF4A and the scaffolding protein 
eIF4G [93]. The RNA helicase eIF4A mediates the unfolding of the RNA secondary structure 
[94]. Unwinding of the secondary structure is assisted by eIF4H and eIF4B and promotes the 
formation of the initiation complex [94]. eIFs 1, 1A, 2, 3 and the Met tRNAi are preassembled 
to the 43S preinitation complex that is recruited to the 5’ cap of the mRNA by the eIF4F 
complex [95]. The scaffolding protein eIF4G links the eIF4F complex to the ribosomal subunit 
by joining with eIF3, which is directly associated with the ribosome of the preinitation 
complex [96]. The whole preinitiation complex then scans downstream until the start codon is 
found, which is complementary to the Met tRNAi. A suitable match to the start codon triggers 
the arrest of the preinitation complex. Hydrolysis of GTP in the eIF2-GTP-Met tRNAi ternary 
complex results in release of eIF2-GDP and other eIFs and allows joining of the 60S 
ribosomal subunit [97]. eIF1 and eIF1A discriminate against initiation at AUG triplets in 
suboptimal context by blocking the full hydrolyzation of eIF2-GTP [97]. Codons that differ 
from the optimal context as described by Kozak et al. may be bypassed [98]. Finally, the 80S 
initiation complex that is competent of protein synthesis is formed. 
The initation step is rate limiting to the whole translational process [99]. Translation efficiency 
of different mRNAs varies and depends to a great extent on features of 5’-UTR that influence 
the scanning process and start codon selection [100]. Certain RNA secondary structures 
constrain the interaction of the preinitiation complex with the mRNA or the scanning of the 5’-
UTR [101]. Also decoy start codons and upstream open reading frames impede the 
recognition of the correct start codon. Some mechanisms to overcome these limitations of 
ribosome scanning have been described in viruses. For example, leaky scanning enables the 
preinitiation complex to skip start codons that differ from the optimal context [102]. Bypassing 
of secondary structures of the 5’-UTR via ribosome shunting was also observed in viruses 
[103]. In mammalians, translation of the stress response gene ATF4 is regulated by 
ribosome reinitiation [104, 105]. Reinitiation allows the preinitiation complex to resume 
translation at the start codon after reading of upstream ORFs without detachment. The 
mechanism is active during stress when eIF2 phosphorylation results in reduced rate of 
preinitiation complex formation and global downregulation of translation.  
Besides the 5’-UTR also some features of the 3’-UTR were found to influence translation 
efficiency. The length of the poly(A) tail determines not only mRNA stability but regulates 
translation initiation as well. Poly(A) binding protein (PABP) associates with the preinitiation 
complex by interaction with eIF4G resulting in a loop conformation of the mRNA [106, 107]. 
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Interaction with PABP is thought to stabilize translation initiation by enhancing the 5’cap 
binding of the preinitiation complex and by stimulating 60S ribosomal subunit joining. 
Regulation of translation initiation 
eIFs that recognize the 5’ cap structure and activate the mRNA for the binding of the 
preinitiation complex are subject to many regulatory mechanisms (Figure 5). Protein 
synthesis is delimitated during stress conditions or starvation [108]. Deactivation of eIFs 
allows a global, fast and transient reduction of the translation rate. The main target of 
translation control is the cap binding protein eIF4E. Direction of the eIF4F complex to the 
mRNA 5’cap structure by eIF4E is required for subsequent joining of the ribosomal subunit 
and translation initiation by ribosomal scanning. A protein family of eIF4E binding proteins 
(4E-BPs) competes with eIF4G for the joined eIF4E binding site thereby inhibiting the 
arrangement of the eIF4F complex [109]. Interaction of 4E-BPs with eIF4E is regulated by 
phosphorylation. Hypophosphorylated 4E-BPs have a high binding affinity, whereas 
phosphorylated 4E-BPs interact only weakly with eIF4E [110]. 4E-BP phosphorylation is 
performed by the mammalian target of rapamycine (mTOR) kinase, which is a part of the 
PI3K/Akt signaling cascade [110]. The PI3K/Akt pathway is triggered by diverse tyrosine 
kinase receptors in response to growth factors or intergins. mTor has several 
phosphorylation targets that are involved in the cap recognition process including eIF4G and 
S6 kinases (S6K) [111]. S6K in turn activates eIF4B resulting in enhanced interaction with 
eIF3. Another substrate of S6K is Pdcd 4, which is ubiquitinylated and degraded upon 
phosphorylation [112]. Pdcd 4 acts as tumor suppressor by binding to and inactivating the 
RNA helicase eIF4A. Another pathway essential for translation control is MAPK signaling, 
which regulates phosphorylation of the cap binding protein eIF4E by Mnk 1, Mnk 2 and p38 
kinases [113]. Mnk 1 and Mnk 2 are part of the MEK/ERK cascade, while p38 is downstream 
of a second independend MEK signaling cascade [114]. Both pathways are regulated by Ras 
in response to growth factor signaling. Deactivation of eIF4E by impaired phosphorylation or 
increased 4E-BP binding leads to reduced cap dependent phosphorylation [115]. Another 
mechanism that specifically regulates cap dependent translation is mediated by micro RNAs 
(miRs). miRNAs are part of a major post transcriptional control mechanism of gene 
expression. Estimated 10.000 mRNAs of the transcriptome are subject to miR regulation 
[116].  miRs are 22nt short double stranded RNAs that are integrated into a protein complex 
referred to as RNA induced silencing complex (RISC) [117]. The RISC complex recognizes 
complementary RNA sequences within the 3’-UTR and impairs expression of a specific 
mRNA subset [118]. Different mechanisms have been proposed for miR mediated regulation 
of gene expression. Recently, it was reported that the RISC complex competes with eIF4E 
for the cap structure and thereby inhibits cap-dependent but not IRES-mediated translation 
[119, 120]. Repressed mRNAs accumulate in P-bodies, which contain enzymes for RNA 
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degradation [121]. miRs and their target mRNAs were also found to accrue in stress granules 
indicating that miRs are involved in the regulation of the cellular stress response [122]. 
Another important stress induced regulatory mechanism affects not only the cap recognition 
but the whole translation initiation process. The PI3K/Akt signaling is regulated by amino acid 
availability and the cellular oxygen level. PI3k/Akt mediated stress response leads to 
phosphorylation of eIF2 at the α subunit. Phosphorylated eIF2α is a competitive inhibitor of 
eIF2B, which mediates the hydrolysis of eIF2-GDP during translation initiation [123]. 
Impaired release of eIF2-GTP from the initiation complex results in a reduction of the 
translation rate. Four different kinases that are triggered by different kinds of cellular stress 
phosphorylate eIF2α at the same residue leading to a similar stress response [124]. PKR is 
activated by double stranded RNA during viral infections, PERK reacts to unfolded proteins 
in the endoplasmatic reticulum, HRI is activated by heme deprivation and amino acid 
starvation triggers GCN2 [124].  
 
Figure 5: Regulation of translation initiation. The activity of translation initiation factors is regulated 
by the MAPK and PI3K pathway in response to growth factor signaling or cellular stress. (adapted 
from [125]) 
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Translation initiation by internal ribosome binding 
Certain mRNAs are capable to circumvent the common translation initiation mechanism of 
ribosome scanning. A structural motif of the RNA referred to as internal ribosome entry site 
(IRES) that is located in the 5’-UTR directly upstream of the start codon allows straight 
binding of the preinitation complex [126]. Translation is initiated immediately without 
scanning. Therefore IRES mediated translation is independent of the cap structure and 
insensitive to regulatory mechanisms that reduce global protein synthesis by deactivation of 
the cap binding protein eIF4E [127]. This alternative form of translation initiation was initially 
described in poliovirus and encephalomyocarditis virus [128, 129]. Polioviruses shut off 
protein synthesis of infected host cells. The viral 2A protease was found to cleave the eIF4E 
binding site of the scaffolding protein eIF4G, preventing the assembling of the preinitation 
complex at the 5’ cap structure of the mRNA [130]. Consequently, the first cellular IRES 
element from the immunoglobulin heavy chain binding protein (BIP) was found due to its 
continued translation in poliovirus infected cells [131, 132]. A small but growing number of 
cellular mRNAs that confer IRES mediated translation have been described since [133, 134]. 
They are expressed during physiological conditions that require a transient downregulation of 
translation such as cell cycle progression, differentiation, cellular stress and apoptosis [108, 
135]. Cellular or viral IRESs elements generally display variations in their secondary 
structure, sequence composition and length [126, 136]. Viral IRESs are divided into subtypes 
by structural similarities [136]. Secondary structure and isolated motifs of the primary 
sequence are conserved among species and viral subtype. The set of initiation factors that 
are required for internal initiation depends on the IRES type. IRES of picorna viruses need 
the complete preinitiation complex except eIF4E, but they don’t have to compete with the 
host cell for eIFs since cap dependend translation is shut off by 2A protease [130, 137]. 
Picornavirus IRESs are long and highly structured. Their initiation is stimulated by IRES 
transacting factors (ITAFs) that are thought to stabilize the complex conformation of the 
secondary structure [138]. In contrast, the IRES of hepatitis C virus don’t require the eIF4F 
complex at all and internal initiation is mediated by eIF3 in cooperation with eIF2 or eIF4B 
[139, 140]. The ability to use eIF4B instead of eIF2 may enable translation when eIF2 is 
deactivated by the host cell. Notably, the cricket paralysis virus IRES initiates translation 
independent of all eIFs and does not even require tRNAi [141]. The IRES mimics the 
anticodon stem loop of the tRNAi and contains also a start codon. In contrast to relatively 
compact viral IRES structures, cellular IRES elements can be composed of multiple short 
motifs that are arranged over a longer stretch of the 5’-UTR [142]. Regions between these 
IRES motifs are not essential for IRES activity. Secondary structures of cellular IRES are 
less well studied and show a greater diversity than viral IRES [143].  A common IRES 
structure motif was not yet identified [144]. There seem to be several distinct mechanisms for 
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ribosome recruitment and translation initiation. Most cellular IRES do not require eIF4E or 
intact eIF4G but depend on eIF4A and eIF3, suggesting that the IRES element needs to be 
remodeled for initiation. Recently, the Src- kinase mRNA was reported to contain the first 
IRES element that seems to be able of direct binding to the 40S ribosomal subunit [145]. 
Several ITAFs were found to support cellular IRES activity including for example the 
multifunctional La protein, polypyrimidine tract binding protein (PTB), poly(A) binding protein 
(PABP) and different heterogeneous nuclear ribonucleoproteins (hnRNPs) [127]. ITAFs are 
believed to enhance the interaction between the IRES structure and components of the 
translation initiation complex. The exact mechanism is not known but ITAFs are thought to 
remodulate partial motifs of the IRES structure to promote ribosome binding or to function as 
initiation factors that mediate ribosome recruitment [146]. IRES mediated translation of Apaf-
1 is enhanced by upstream of N-Ras (UNR), which promotes the binding of the second ITAF 
PTB [147]. Both ITAFs unfold the RNA secondary structure and these changes of RNA 
conformation allow the ribosome recruitment. Other IRES were found to be capable of direct 
base pairing with the rRNA by a Shine-Delgarno like mechanism [148].  A prominent 
example for well understood modular IRES is c-myc. The secondary structure of the c-myc 
IRES was predicted by enzyme mapping [149]. Mutation experiments revealed that 
pseudoknots in the first domain seem to attenuate IRES activity, suggesting that ITAFs which 
bind to this domain open this pseudoknot structures to enhance IRES translation [149]. The 
main IRES activity was tracked down to a small region of 50 nts [150]. Studies showed that 
the sequence and not the structure of this region is important for IRES activity [150]. 
Together these data indicate that cellular IRES are not compact motifs of the RNA secondary 
structure but rather involve a number of small regions with a specific primary or secondary 
structure that interact with ITAFs or components of the translation machinery.  
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3.4. Physiological significance of internal translation initiation 
ITAFs regulate cell fate decisions 
IRES mediated translation promotes initiation of cellular mRNAs with highly structured 5’-
UTR, which are less efficiently translated under normal physiological conditions [151]. More 
importantly, IRES translation is enhanced when cap dependent translation is compromised, 
allowing the translation of important regulatory factors during cellular stress conditions, 
mitosis, hypoxia or nutrient deprivation [152]. It is believed that IRES translation becomes 
more competitive for available translation factors and ribosomes when cap dependent 
translation is impaired [108]. Many mRNAs that confer IRES translation encode factors that 
protect cells from stress or apoptosis and therefore play an important role in cell fate 
decisions [153]. It has been shown that different mRNA subsets are induced in response to 
diverse physiological stress conditions IRES translation. This differential activation of IRES 
translation is regulated by ITAFs, which bind selected IRES structures and positively 
modulate their activity (Table 1). Most ITAFs belong to the group of hnRNPs that are known 
to shuttle between the nucleus and cytoplasm [154]. The ITAF compartimentalization is 
regulated in response to cellular conditions that impair cap dependent translation. The exact 
mechanism how subcellular localization of ITAFs affects IRES translation is not known. One 
hypothesis proposes the translocation of ITAFs to the cytoplasm where they interact with 
target mRNAs and support translation [154]. Another theory suggests that ITAFs bind their 
responding mRNAs in the nucleus and thereby sequester it from the translation machinery 
until they translocate into the cytoplasm [155]. Signaling events that regulate the cytoplasmic 
translocation have not yet been identified for most ITAFs. In some cases such as for hnRNP 
A1, stress induced phosphorylation was shown to trigger cytoplasmic localization and 
enhanced binding affinity for IRESs [156, 157]. Despite the involvement of IRES translation 
in the regulation of various physiological and pathophysiological conditions there is only 
moderate progress in the clarification of underlying mechanisms. A major problem of 
characterizing signaling events that regulate IRES translation arises from the complexity of 
mechanisms that control internal initiation. Great variations in the requirement of eIFs and 
ITAFs for initiation of diverse IRES elements suggest different underlying mechanisms.  
Moreover, the majority of proteins that mediate internal initiation are master regulators of 
proliferation, survival or apoptosis [134]. Their expression is tightly regulated on multiple 
transcriptional and translational levels. Recent studies provide evidence for the significance 
of IRES translation in regulating angiogenesis, mitosis and cell survival. 
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Table 1: List of ITAFs and their mRNA targets [127]  
 
IRES mediated translation during angiogenesis 
Angiogenesis describes the formation of new or growth of preexisting vessels.  During wound 
repair angiogenesis plays an important role in meeting the increased oxygen and nutrient 
supply of regenerating tissue [17]. The same mechanism is activated in tumor cells and plays 
an essential role in tumor growth and metastasis [17]. VEGF regulates proliferation, 
proteolytic activity and migration of endothelial cells and therefore is the key mediator of 
angiogenesis [158]. VEGF expression is tightly regulated at diverse levels including 
transcription and alternative splicing. Recent studies suggest a pivotal role for IRES 
regulated translation during angiogenesis.  The VEGF-A mRNA harbours two IRESs. The 
upstream IRES-B translates a protein isoform (L-VEGF) that is 180 nts amino acids longer 
than the isoform translated by the downstream IRES-A [159]. L-VEGF is cleaved into a C-
terminal fragment that is secreted and a intracellular N-terminal fragment. The proteolytic 
cleavage generates the VEGF121 isoform that is predominantly expressed during 
tumorigenesis and processes higher angiogenic activity than other VEGF isoforms [159]. 
IRES-A mediated translation generates secreted VEGF isoforms only [159]. Interestingly 
IRES-B but not IRES-A translation is impaired by microRNA-16 (miR-16) [160]. Translational 
repression by miR-16 does not affect mRNA stability or VEGF transcription. The miR-16 
binding site is located within the 3’-UTR of VEGF-A mRNA near the ITAF binding site for 
hnRNP L, which might be involved in the miR-16 induced reduction of IRES translation [161]. 
miR-16 therefore might function as a repressor of hypoxia induced of VEGF IRES translation 
and subsequent angiogenesis.  
IRES mediated translation during mitosis 
IRES translation of CDK-1, CDK-11 and BCL-2 was found to be regulated during mitosis. 
Modulation of IRES mediated translation plays a critical role in cell cycle progression during 
the G2/M phase when cap dependent translation is compromised (Figure 6) [162, 163]. IRES 
translation of CDK-11/p58 that is involved in spindle formation was shown to be regulated by 
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an ITAF signaling cascade. The pathway starts with cytoplasmic accumulation of the ITAF 
hnRNP C1/C2, which enhances IRES driven translation of unr [164]. Unr is another ITAF that 
in turn positively modulates IRES translation of p58 [164]. Activation of unr is regulated by a 
negative feedback loop that is mediated by unr itself and is controlled by cytoplasmic 
accumulation of the PTB ITAF [164]. The whole signaling mechanism is based on IRES 
translation and therefore allows a precise modulation of p58 levels under conditions when 
cap dependent translation is severely repressed. Furthermore, IRES driven protein synthesis 
of CDK-1 and BCL-2 was found to prevent cell apoptosis during mitosis [165, 166]. 
Proteolytic cleavage of the eIF4G family member DAP5 during apoptosis results in a 
truncated protein that positively modulates IRES translation of CDK-1 and BCL-2 and 
promotes cell survival [166]. Additionally, CDK-1 expression during mitosis is regulated by 
AKT mediated phosphorylation of hnRNP A1 [157]. Phosphorylation of hnRNP A1 renders 
the ITAF inactive and prevents the enhancement of CDK1 IRES translation. Also cyclin D1 
IRES translation is activated during mitosis by cytoplasmic translocation of the La ITAF [167]. 
 
 
 
Figure 6: ITAF signaling during cell cycle progression. IRES translation of CDK-11 is during G2/M 
transition is regulated by an ITAF signaling cascade. IRES mediated synthesis of BCL-2 and CDK-1 
prevents apoptosis during cell cycle progression [162]. 
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3.5. Translation regulation during tumorigenesis 
Dual translation initiation mechanism of oncogenes 
The central pathways that are deregulated during tumor progression also control translation 
activity. MAPK and PI3K signaling cascades drive tumorigenesis and regulate translation in 
multiple ways [168]. Aberrant activation of PI3K Akt signaling in response to growth 
hormones or through PTEN mutations is frequently observed in human cancers resulting in 
phosphorylation of mTOR complex 1 (mTORC1) [169]. Active mTORC1 promotes cap 
dependent translation through phosphorylation of eIFG1 and inactivation of 4E-BPs [170]. 
Other downstream effectors of mTORC1 are the S6 ribosomal protein kinases S6K1 and 
S6K2 [170]. S6K1 facilitates tumor proliferation by promoting eIF4A helicase activity through 
degradation of PDCD4 and activation of eIF4B [111, 112]. mTORC1 is also activated by 
ERK, the effector kinase of the Ras MAPK pathway [170]. Moreover, the promotion of 
tumorigenesis by Ras MAPK signaling depends on stimulation of translation through 
phosphorylation of eIF4E by ERK regulated MNK1 and MNK2 [171]. Deregulation of 
translation during tumorigenesis primarily affects those mRNAs that contain an IRES 
element. Increased availability of initiation factors that are required for the ribosome scanning 
mechanism, such as the cap binding protein eIF4E, eIF4G or the RNA helicase eIF4A 
stimulates cap dependent translation of a small mRNA subset that are usually translated with 
a low efficiency due to the IRES secondary structure [172]. Physiological conditions such as 
amino acid starvation, growth arrest, apoptosis or hypoxia that occur during cancer 
progression result in transient downregulation of cap dependent translation [152]. Important 
key factors that are involved in the regulation of these conditions contain an IRES element 
that initiates translation when the cap binding complex is deactivated. Interestingly many of 
these key regulatory factors are considered oncogenes that drive tumorigenesis [134]. The 
dual mechanism of cap dependent and IRES mediated translation allows a permanent 
enhanced translation of important factors such as c-myc, VEGFA or BCL-2 [173]. 
Deregulation of the mRNA 5’ cap-structure recognition 
Tumors frequently develop an enhanced ability to confer cap dependent translation by 
upregulation of eIF4F activity through diverse mechanisms [174]. The cap binding protein 
eIF4E is overexpressed in various cancers and is strongly associated with decreased patient 
survival [175]. eIF4E is required for the oncogenic activity of H-Ras and for myc induced 
transformation of primary fibroblasts [176, 177]. Furthermore, NIH-3T3 cells can be 
transformed by ectopic eIF4E overexpression [178]. The tumor promoting activity of eIF4E is 
based on the increased preferential translation of specific mRNAs that have a highly 
structured 5’-UTR [172]. These mRNAs are thought to be less efficiently translated due to 
reduced competitiveness in the ability to recruit or retain the eIF4F complex or to unwind the 
secondary structure during ribosome scanning. mRNAs with highly structured 5’-UTRs that 
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translationally upregulated in response to increased eIF4E activity encode proteins involved 
in angiogenesis (VEGF A) and cell cycle progression (myc, cyclin D (CCND) 1, ornithine 
decarboxylase (ODC) 1, FGF2) [179, 180]. Recently, a study revealed increased 
phosphorylation of eIF4E in 67% of various human cancers compared to 30% in adjacent 
noncancerous tissue [181]. The phosphorylation grade correlated with tumor aggressiveness 
in many but not all cancer types. A possible reason for this could be the 4E-BP mediated 
counter regulation opposing eIF4E activity. Hypophosphorylated 4E-BP competitively binds 
eIF4E preventing the formation of the eIF4F cap binding complex. Deactivation of 4E-BP or 
decreased levels of 4E-BP 1 and 2 were shown to correlate with increased cancer 
progression and reduced survival [182, 183]. While increased availability of eIF4E leads to 
enhanced cap dependent translation of mRNAs that contain an IRES element, elevated 
abundance of eIF4G results in stronger IRES mediated translation [184]. Transcripts that 
contain an IRES element can utilize the eIF4G to drive IRES translation in absence of eIF4E. 
Cap dependent translation requires the cap binding protein eIF4E and does not profit from 
the sole elevation of eIF4G abundance. High levels of eIF4G 1 in the absence of deregulated 
eIF4E or 4E-BP were found in inflammatory breast cancer and drives translation of 
angiogenic and survival factors [185]. Hypoxia induced overexpression of eIF4G1 and 4E-
BP1 functions as switch from cap dependent to IRES mediated translation in animal models 
of breast cancer. 
Deregulation of the mRNA ribosome interaction 
The eIF3 complex is composed of multible subunits, but only a few are essentially required 
for translation initiation [186]. They form a core complex that mediates the bridging function 
between eIF4F and the ribosome. Other subunits are thought to promote the interaction of 
eIF3 with specific mRNAs [186]. eIF3 subunits therefore play diverse roles in cancer. The 
oncogenes eIF3a, eIF3c and eIF3h are frequently overexpressed in human cancers and 
ectopic expression of these subunits was found to induce the transformation of NIH-3T3 cells 
[187]. Increased expression of eIF3a, eIF3c, and eIF3h leads to the activation of protein 
synthesis and to elevated translation rates of mRNAs that usually have a low translation 
efficiency including myc, FGF 2, Odc 1 and Ccnd1 [187]. Furthermore, eIF3a was found to 
downregulate the cell cycle inhibitor p27 (CDKN1B), thereby promoting cell proliferation 
[188]. In contrast, eIF3e might act as tumor suppressor by inhibiting cell growth and 
promoting apoptosis. eIF3e was found to be downregulated in breast and lung carcinomas 
[189]. 
Uncoupling of stress induced translation impairment  
The role of eIF2 phosphorylation in cancer is complex and depends on the disease stage. At 
early disease stages phosphorylation of eIF2 reduces protein synthesis and allows cells to 
adapt to hypoxic situations [190, 191]. Phosphorylation of eIF2 during hypoxia is mediated by 
Dissertation                                                                                                Michaela Petz 
 25   
PERK and counterregulated by the eIF2 phosphatase GADD34 [192]. Activation of PERK 
can cause tumor quiescence. Therefore, it is likely that PERK is uncoupled from translation 
regulation during tumor progression. An example for this mode of action was described in 
multiple myeloma cells that acquire quiescence by activation of PERK and encounter the 
downregulation of protein synthesis through activation of GADD34 [193]. PKR seems also to 
antagonize tumor progression. Elevated PKR levels were found to be associated with 
carcinoma cell differentiation [179, 194]. Concordantly, more aggressive types of brain 
cancer have elevated levels of eIF2, which might provide a way to escape the 
downregulation of protein synthesis [195].  
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4. Aims 
Interaction of tumor cells with the ECM plays an important role in cell invasion and 
metastasis. Especially LamB1 is involved in the regulation of tumor cell migration and 
angiogenesis. Recent results provide first evidence that the 5’-UTR of the LamB1 mRNA 
contains an IRES motif which directs translational upregulation of LamB1 expression during 
EMT and malignant progression of epithelial hepatocytes. Therefore IRES driven translation 
of LamB1 and its regulation by ITAFs might be a molecular mechanism of particular 
relevance for tumorigenesis. 
Project aims are based on the hypothesis that the 
(i) IRES element within the 5’-UTR of the LamB1 transcript is essential for cap-
independent translation 
(ii) increased expression of LamB1 in mesenchymal derivatives of carcinoma cells 
primarily results from enhanced IRES mediated translation of the LamB1 transcript 
(iii) minimal IRES sequence of LamB1 interacts with ITAFs which allow efficient cap-
independent translation of LamB1  
(iv) interaction of ITAFs with the IRES of LamB1 is regulated during tumor progression 
(v) translational upregulation of LamB1 expression during EMT depends on the 
cooperation of Ras and TGF-ß signaling 
The aim of this work is the identification of the IRES motif within the 5’-UTR of the LamB1 
transcript and its interacting ITAFs that regulate IRES-driven translation during tumor 
progression. Subsequent aims involve the dissection of signaling pathways that regulate 
ITAFs and control IRES-mediated translation of LamB1. 
specific aims include to 
(i) evaluate  transcriptional mechanisms that might be additionally involved in the 
regulation of LamB1 protein expression during tumorigenesis 
(ii) determine the minimal IRES element that is required for cap-independent translation 
of the LamB1 transcript 
(iii) identify ITAFs that interact with the LamB1 5’-UTR and modulate IRES mediated 
translation efficiency 
(iv) identify the signaling pathways that  regulate ITAFs involved in IRES driven 
translation of LamB1 by interfering with TGF-ß and Ras signaling 
(v) evaluate the ratio between cap-dependent and IRES-dependent translation of LamB1 
during EMT 
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5. Experimental setup: 
  Regulation of LamB1 translation during EMT was studied in a murine HCC model 
system based on immortalized hepatocytes that were isolated from a p19ARF(-/-) mouse 
(MIM1-4, Figure 7). These cells become tumorigenic after retroviral transmission with 
oncogenic Ha-Ras (MIM-R). Epithelial MIM-R cells undergo EMT in response to TGF-
ß treatment by the cooperation of oncogenic Ras and TGF-ß signaling. They acquire 
a mesenchymal phenotype, establish an autocrine TGF-ß loop and become 
metastatic (MIM-RT).  
 
Figure 7: murine model of hepatocellular EMT. 
 To investigate the involvement of transcriptional mechanisms in the regulation of 
LamB1 during tumor progression, the expression of mRNA isoforms in different 
human HCC cell lines was analyzed by Northern blotting and RACE-PCR of the 5’- 
and 3’-UTR.  
 A bicistronic reporter system was employed to determine the IRES activity of LamB1 
(Figure 8). The LamB1 5’-UTR was placed between two reporter into a bicistronic 
vector. Translation of the first reporter is cap-dependent while cap-independent 
translation of the second reporter is mediated by the IRES element within the 5’-UTR 
of LamB1. The minimal XIAP IRES element was used as positive control for IRES 
activity and the empty vector served as negative control. 
   
 Figure 8: bicistronic reporter system 
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 The LamB1 5’-UTR was screened for cryptic promoter or splice sites in order to verify 
the IRES activity that was detected with the bicistronic reporter system. Cryptic 
promoter or splice sites may result in truncated transcripts of the second reporter that 
could be mistaken for IRES activity. The ratio of first and second reporter mRNA was 
quantified by qPCR to detect aberrant transcripts (Figure 9). The LamB1 5’-UTR was 
cloned upstream of a firefly luciferase reporter and the CMV promoter was removed 
from the vector in order to exclude the presence of a cryptic promoter within the 5’-
UTR (Figure 10). 
 
   
Figure 9: qPCR for truncated transcripts Figure 10: cryptic promoter assay 
 The minimal IRES element that is required for full IRES activity of LamB1 was 
determined by performing sequence deletions of the 5’-UTR in steps of 50 nts starting 
from either the 5’ or 3’ terminus. IRES activities of the truncated fragments were 
analyzed with bicistronic vectors. 
 ITAFs that interact with the LamB1 IRES were identified by streptavidin-tethered RNA 
affinity purification (Figure 11). The LamB1 5’-UTR was cloned into the pTrap vector 
that contains a T7 promoter and two S1 aptameres which specifically bind steptavidin. 
In vitro transcription resulted in a fusion transcript of the 5’-UTR and S1 aptameres. 
The RNA transcript was applied to magnetic streptavidin beads and incubated with 
cell lysate. Beads were washed and the RNA protein complex was eluted with biotin. 
Proteins that specifically associated with the RNA were analyzed by SDS-PAGE and 
silver staining and further identified by Western blotting. Results were verified by 
performing a RNA protein immunoprecipitation with the identified ITAF (Figure 12). 
RNA interacting proteins were in vivo crosslinked by UV irradiation und precipitated 
with an antibody against the ITAF. The precipitated RNA protein complex was 
isolated, treated with DNase I and proteinase K and used for RT-PCR.  
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  Figure 11: RNA affinity purification  Figure 12: RNA Immunoprecipitation 
 Genetically modified cell lines and pharmalogical inhibitors were used to study the 
signaling pathway involved in the regulation of the La ITAF that was found to be 
associated with the LamB1 IRES (Table 2). To impair PDGF signaling, a dominant 
negative (dn) version of the PDGF receptor α was introduced into MIM-R cells by 
retroviral transmission resulting in MIM-RdnP. Murine hepatocytes that express 
either oncogenic Ha-Ras (MIM-R), a S35-V12 Ras mutant that selectively activates 
MAPK (MIM-S35) or a C40-V12 Ras mutant that activates PI3K signaling (MIM-C40) 
were employed to further dissect the pathways involved in La regulation. These cell 
lines undergo EMT (MIM-RT, MIM-RTdnP, MIM-ST) or acquire a scattering 
phenotype (MIM-CT) in response to TGF-β. To verify and analyze the regulation of 
LamB1 IRES translation by La, cell lines with a stable knockdown of La were 
generated by retroviral transmission of shRNA. Pharmacological inhibitors against 
TGF-β, MAPK or PI3K signaling were used. 
Table 2: Cell lines established to analyze the pathways involved in the regulation of La.  
MIM-RdnP MIM-RTdnP dnPDGF receptor 
MIM-RshLa MIM-RTshLa shRNA against La 
MIM-C40 MIM-CT PI3K activation  
MM-S35 MIM-ST MAPK activation  
Dissertation                                                                                                Michaela Petz 
 39   
6. Conclusions 
The data reveals that translational upregulation of LamB1 during hepatocellular tumor 
progression is directed by an IRES element located within the 5’-UTR of the transcript. IRES 
translation of LamB1 is enhanced by the ITAF La that accumulates in the cytoplasm upon 
EMT and binds the minimal IRES motif. Cytoplasmic accumulation of La is regulated by 
PDGF signaling via the cooperation of the MAPK and PI3K pathway. EMT transformed cells 
establish an autocrine TGF-β loop that triggers PDGF signaling leading to a persistent 
cytoplasmic localisation of La which results in enhanced IRES mediated translation of LamB1 
(Figure 13).  
 
Figure 13: A model for the regulation of IRES mediated LamB1 translation upon hepatocellular EMT.  
In detail the results allow following conclusions: 
(i) LamB1 is not regulated by expression of alternative mRNA isoforms during 
hepatocellular tumorigenesis. Transcript variants that may arise from alternative 
splicing of the 5’-UTR or polyadenylation of the 3’-UTR could not be detected in 
human HCC cell lines. 
(ii) The LamB1 5’-UTR drives cap-independent, IRES mediated translation. IRES activity 
was verified by excluding the presence of cryptic promoter or splice sites within the 5’-
UTR. 
(iii) The IRES structure within the LamB1 5-’UTR is localized between -293 and -1 nts 
upstream of the start codon. This is the minimal sequence that is required for full cap 
independent translation activity of the 5’-UTR.   
Dissertation                                                                                                Michaela Petz 
 40   
(iv) The minimal IRES sequence contains a motif that regulates IRES translation in 
response to TGF-β and starts between -241 and -180 nts upstream of the start 
codon. 
(v) LamB1 expression is translationally upregulated upon TGF-β induced EMT. 
Increased LamB1 levels result from enhanced IRES translation. LamB1 mRNA levels 
remain unchanged and cap-dependent translation rates are not affected by EMT. 
(vi) The ITAF La interacts with the LamB1 5’-UTR in vitro and in vivo and binds to the 
minimal IRES sequence. Increased levels of La associate with the minimal IRES 
sequence in EMT transformed cells. 
(vii) The presence of La enhances LamB1 IRES activity in vitro. Stable knockdown of La 
reduces bicistronic LamB1 IRES activity as well as endogenous LamB1 levels in EMT 
transformed cells. 
(viii) La levels are not regulated upon EMT, but La accumulates in the cytoplasm upon 
short term TGF-β treatment as well as in EMT transformed cells. 
(ix) PDGF signaling is activated by TGF-β upon EMT and regulates the subcellular 
localization of La.  
(x) The synergistic MAPK and PI3K signaling downstream of PDGF might account for 
triggering the cytoplasmic accumulation of La. 
(xi) Besides the persistent PDGF mediated enhancement of LamB1 IRES translation in 
EMT transformed cells, short-term treatment of epithelial cells with TGF-β additionally 
results in transient PDGF receptor expression and cytoplasmic localization of La and 
a slight upregulation of LamB1 IRES translation. This activation of cap-independent 
translation might be a result of cellular stress. 
Concluding remarks: 
Expression of LamB1 in malignant hepatocytes during stress conditions and the PDGF 
driven activation of IRES translation in metastatic tumor cells suggests an important role of 
LamB1 in tumorigenesis.  LamB1 was shown to be involved in the regulation of tumor cell 
migration by integrin and LamR activation. Enhanced cap independent LamB1 translation 
during EMT might therefore be relevant for tumor metastasis. Furthermore, the role of IRES 
mediated LamB1 translation in angiogenesis remains to be investigated. Neovascularisation 
of tumors is induced by hypoxia and involves the IRES mediated translation of HIF-1α, VEGF 
and PDGF. Interestingly, LamB1 was found to regulate endothelial tube formation during 
vascularization. The PDGF triggered enhancement of IRES mediated LamB1 translation 
would allow its expression during stress conditions such as hypoxia. Thus, PDGF signaling 
would be a suitable regulatory mechanism for the activation LamB1 translation during tumor 
angiogenesis. 
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7.1. Abstract 
Both RAS and transforming growth factor (TGF)-β signaling cascades are central in 
tumorigenesis and show synergisms depending on tumor stage and tissue context. In this 
review we focus on the interaction of RAS subeffector proteins with signaling components of 
the TGF-β family including those of TGF-βs, activins and bone morphogenic proteins. 
Compelling evidence indicates that RAS signaling is essentially involved in the switch from 
tumor-suppressive to tumor-promoting functions of the TGF-β family leading to enhanced 
cancer growth and metastatic dissemination of primary tumors. Thus, the interface of these 
signaling cascades is considered as a promising target for the development of novel cancer 
therapeutics. The current pharmacological anti-cancer concepts combating the molecular 
cooperation between RAS and TGF-β family signaling during carcinoma progression are 
critically discussed. 
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7.2. Introduction 
Carcinoma Progression 
The malignant growth and aberrant differentiation of epithelial tissues, collectively designated 
as carcinoma, develop by a multistep process. Most frequently, carcinoma progression leads 
to metastatic spread of primary tumor cells and to colonization in distant organs [1,2]. Six or 
even seven properties have been defined which allow neoplastic cells to acquire and to 
increase malignancy [3-5]. Among these mechanisms are the (i) unlimited replicative 
potential, (ii) evasion of apoptosis, (iii) self-sufficiency in growth signals, (iv) ability to develop 
blood vessel for neoangiogenesis, (v) insensitivity against anti-growth factors such as 
transforming growth factor (TGF)-β, (vi) tissue invasion and metastasis, and (vii) cancer-
related inflammation supported by the tumor-stroma. The sequence of genetic and 
epigenetic events resulting in the malignant progression of carcinoma cells appears to be 
random in a stochastic point of view, but is most frequently accompanied by the loss of 
functional differentiation and the acquisition of a migratory phenotype. The prototypical 
conversion of carcinoma cells to fibroblastoid descendants through transdifferentiation has 
been described as epithelial to mesenchymal transition (EMT), allowing carcinoma cells to 
infiltrate the tumor-stroma and to enter as well as to exit the circulatory system in order to 
generate macrometastasis [6-8]. 
Various stimuli generated by cell autonomous events and the tumor surrounding impinge on 
carcinoma cells to induce the crosstalk between rat sarcoma (RAS) signaling proteins and 
components of the TGF-β superfamily. Important downstream signaling events of RAS 
involved in the cooperation with the TGF-β/Smad family include the (i) RAS-activated factor 
(RAF)/mitogen activated protein kinase (MAPK) extracellular regulated kinase (ERK) kinase 
(MEK)/ERK pathway (RAS-RAF-MEK-ERK signaling), (ii) phosphatidylinositol- 3 kinase 
(PI3K) pathway activating the serine/threonine kinase AKT-protein kinase B (PKB) and the 
transcription factor nuclear factor (NF)-κB, and (iii) additional RAS effectors such as RAS-
related RAL proteins, phospholipase C (PLC)ε, T cell lymphoma invasion and metastasis-1 
(TIAM1), RAS interaction protein-1 (RIN1) and RAS association domain-containing family 
(RASSF) proteins [9,10]. The enormous complexity underlying the convergence of these 
signaling cascades will be summarized and discussed in the light of advanced and novel 
targeted anti-cancer therapies. 
TGF-ß Super Family 
With more than 30 members, the TGF-β super family is the largest human cytokine family 
including TGF-β1-3, activins, nodal, bone morphogenetic proteins (BMPs), growth and 
differentiation factors (GDFs) and anti-Muellerian hormone (AMH). A phylogenetic tree of all 
family members and their receptors can be found in a recent review [11]. Structurally, TGF-β 
cytokines are characterized by cysteine knots which are based on six conserved cysteines 
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forming three intramolecular disulfide bonds. A seventh conserved cysteine is used by most 
ligands for dimerization via an intermolecular disulfide bond [12]. The canonical signaling 
cascade for cytokines of the TGF-β family is the Smad pathway, which can be divided into 
two major branches (Fig. 1). Which branch of the pathway is activated, depends largely on 
the binding and recruitment of specific ligands to different combinations of type I and II TGF-
β family receptors [12,13]. In total, there are seven type I (activin receptor-like kinase, ALK1-
7) and five type II (TGFBRII, ActRII, ActRIIB, BMPRII, AMHRII) receptors, together 
constituting the only mammalian family of transmembrane serine/threonine kinases [11]. 
TGF-β1 and activins first bind their type II receptors, which stabilizes interaction between 
type II and type I receptors and leads to phosphorylation of type I by type II receptors. Some 
BMPs in contrast bind to pre-formed tetramers of type I and type II receptors [13]. The type I 
receptors in turn are responsible for phosphorylation of receptor-regulated (R)-Smads at two 
C-terminal serine residues. ALK4, 5 and 7 phosphorylate R-Smads2 and 3, whereas ALK1, 
2, 3, and 6 phosphorylate the R-Smads1, 5, and 8 (Fig. 1). In general, there is a considerable 
degree of promiscuity in the core Smad activation pathway as (i) several ligands can bind the 
same type II receptor, (ii) most type II receptors can pair with different type I receptors and 
(iii) each R-Smad can be phosphorylated by more than one type I receptor [11,13]. 
Nevertheless, most ligands activate exclusively either the Smad2/3 branch (activins, nodal, 
myostatin) or the Smad1/5/8 branch (most BMPs). The most notable exception is TGF-β1, 
which on the one hand activates Smad2/3 via TGFBRII and TGFBRI-ALK5 in epithelial cells 
and on the other hand has been shown to activate Smad1/5/8 either dependent on or 
independent of ALK1 in endothelial cells and additional cell types [14-16]. For relaying the 
signal into the nucleus, all R-Smads form a complex with the single common mediator (Co-
)Smad4. The remaining two members of the Smad family (Smad6, Smad7) are classified as 
inhibitory (I)-Smads because they block signal propagation of the BMP branch (Smad6) or of 
all TGF-β family members (Smad7). However, a TGF-β and BMP-independent role of Smad7 
has recently been suggested [17]. In the nucleus Smad complexes cooperate with a number 
of different transcription factors and co-activators or co-repressors to regulate the 
transcription of target genes [18]. Except for Smad2, all R-Smads as well as Smad4 have 
direct DNA binding activity. Phospho-Smad2/Smad4 complexes interact for instance with 
FOXH1 (forkhead box H1, formerly FAST1) and bind to ARE (activin response element) 
sequences in target gene promoters [19], whereas BMP-activated Smads regulate target 
genes via BRE (BMP response element) sequences in cooperation with Runx e.g. family 
transcription factors [20]. In addition to Smad-dependent signals, TGF-β can initiate a Smad-
independent signaling pathway via the E3-ligase TRAF6 and subsequent activation of the 
MAP kinase kinase kinase TAK1 [21]. Activation of the MAPK cascade by TGF-β has also 
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been described to occur via tyrosine kinase activity of the TGF-β type I receptor resulting in 
receptor autophosphorylation and recruitment of the adaptor protein ShcA [22]. 
The TGF /Smad pathway cooperates with RAS signaling at three different levels (Fig. 1). 
First, a crosstalk between TGF-β family receptors and RAS has been demonstrated by 
phosphorylation of RAS pathway components through TGF-β family receptors. Secondly, 
Smad proteins are phosphorylated by RAS-regulated kinases (Fig. 2), which controls their 
nuclear/cytoplasmic distribution and activity. Thirdly, Smad- and RAS-dependent 
transcription factors interact and cooperatively regulate target gene transcription. 
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7.3. Cooperation of Ras with the TGF-ß superfamily 
The Synergy of RAS and TGF-β Signaling 
TGF-β acts as a potent inhibitor of epithelial cell proliferation through its capability to induce 
cytostasis by increasing expression of the cyclin-dependent kinase inhibitors (CDKIs) 
p15Ink4B and p21Cip1 and by repression of c-MYC as well as of inhibitors of differentiation 
(IDs). These modulations (i) cause differentiation and a block of cell cycle progression, (ii) 
stimulate cell death, and (iii) repress cytokine and chemokine expression [23]. The tumor-
suppressive functions of TGF-β signaling are observed in epithelial tissues under 
physiological conditions and are mostly active during early stages of tumorigenesis. 
Importantly, loss of sensitivity to the effects of TGF-β through bypassing the pathway via 
selective mutations of TGFBRs or Smad4 has a pivotal role in the progression of a variety of 
carcinomas [24]. In contrast to the tumor suppressor activities of TGF-β, a multitude of 
studies demonstrated pro-oncogenic functions of TGF-β signaling by dysregulation of CDKIs, 
altered production of extracellular matrix (ECM) constituents via mobilization of 
myofibroblasts, autocrine regulation of mitogens, induction of cell motility and EMT, 
suppression of immunosurveillance, stimulation of angiogenesis and priming of tumor cells 
towards metastasis [25-27]. Most remarkably, increased expression and secretion of TGF-β1 
in hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), gastric, colorectal, 
breast, and prostate carcinoma correlates with poor prognosis, indicating TGF-β as a tumor 
promoter which facilitates aggressiveness of carcinoma [25,28]. The mechanisms of the 
dichotomous role of the TGF-β pathway and how TGF-β signaling is switched from being 
tumor-suppressive to tumor-promoting is just beginning to be resolved. 
A large body of literature indicates a prominent role of RAS signaling in the conversion from 
anti- to pro-oncogenic TGF-β signaling, however, the mechanisms of the synergy between 
oncogenic RAS and TGF-β signaling is still not fully understood [29]. Almost all of these 
investigations revealed that cancer cells undergo an increase in malignancy and retain a 
functional TGF-β/Smad core signaling, while tumor-suppressive functions of the canonical 
TGF-β/Smad pathway are concomitantly inhibited. RAS has been shown to mainly interfere 
with TGF-β/Smad signaling at the level of Smad2/3 activation and the composition of Smad-
dependent transcription factor complexes (Fig. 1). 
Involvement of the RAS Subeffector Pathways MAPK, PI3K and RhoA 
Previous studies on keratinocyte, mammary, prostate and hepatocyte carcinogenesis models 
showed a synergistic cooperation of TGF-β and RAS to induce progression to 
undifferentiated, invasive tumors [30-34]. TGF-β and RAS signaling also cooperates in the 
intestinal epithelium where overexpression of K-RAS in combination with deletion of TGFRII 
generated metastatic adenocarcinomas with activated epidermal growth factor (EGF) 
signaling independent of Wnt/β-catenin [35]. Neither oncogenic K-RAS nor inactivation of 
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TGFRII on its own was able to induce colorectal tumors. In MDCK cells, sustained activation 
of RAF-MAPK induced EMT and cell invasion dependent on the RAFmediated autocrine loop 
of TGF-β [36]. Activation of RAF caused endocytosis and ubiquitin-dependent lysosomal 
degradation of E-cadherin [37], and inhibited the ability of TGF-β to induce apoptosis without 
affecting growth retardation. These data demonstrate that the RAF-MAPK pathway 
synergizes with TGF-β/Smad signaling in promoting malignancy [36]. In particular, 
hyperactivation of MEK-ERK signaling was responsible for the escape from TGF-β-induced 
apoptosis in HCC cells by impairing the upregulation of the NADPH oxidase NOX4, which is 
essential for mitochondrial-dependent apoptosis [38,39]. 
Cooperation of hyperactive RAF-MAPK and TGF-β/Smad signaling was required for EMT 
and metastasis of mammary epithelial cells in vivo, whereas activation of PI3K caused 
protection against TGF-β-induced apoptosis and scattering of cells leading to tumorigenesis 
in the absence of metastatic colonization [29,40]. In malignant hepatocytes, MAPK signaling 
in collaboration with TGF-β signaling was necessary and sufficient to induce EMT and to 
promote resistance to TGF-β-mediated cell cycle arrest as well as induction of apoptosis, 
whereas PI3K activation and TGF-β failed to form tumors [41]. Interestingly, the synergy of 
RAS and TGF-β signaling induced the secretion and autocrine regulation of platelet-derived 
growth factor (PDGF) by upregulation of PDGF receptors upon EMT, which resulted in PI3K 
activation and nuclear β-catenin accumulation [42-44]. 
Oncogenic K-RAS-ERK signaling in pancreatic adenocarcinoma promoted TGF-β-induced 
transcriptional downregulation of the tumor suppressor PTEN (phosphatase and tensin 
homolog) by simultaneous activation of PKB-AKT in a Smad4-independent manner which 
might provide a switch from growth suppression to growth promotion in pancreatic cancer 
[45]. Similarly, TGF-β-induced cell migration and EMT of mammary epithelial cells depended 
on the PI3K-AKT pathway and required Rho GTPase function. This was shown by the 
pharmacological and genetic interference with the PI3K-AKT pathway which blocked Smad2 
phosphorylation and transcriptional responses induced by TGF-β [46]. TGFBRI-ALK5-
dependent activation of the p38MAPK pathway was required for TGF-β- mediated EMT of 
breast carcinoma cells which associated with Rac1 activation and upregulation of 
tropomyosins (TPM1) necessary for TGF-β-induced stress fiber formation during EMT 
[47,48]. Interestingly, the upregulation of TPM1 is delayed by several hours as compared to 
immediate-early and intermediate response genes of TGF-β [49,50]. RAS appears to inhibit 
late-response but not immediate-early response TGF-β target genes as it did not affect the 
immediate phosphorylation of R-Smads and their nuclear translocation, but it reduced 
nuclear presence of Smad4 at later times [49]. Noteworthy, RAS-ERK signaling suppressed 
Smad-dependent expression of TPM1 and inhibited stress fibers in metastatic breast cancer 
cells which allowed invasion of EMT transformed cells. H-RAS-V12 prevented binding of 
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Smads to the TPM1 promoter by forcing CRM1-dependent  nuclear export of Smad4 [51]. 
Animal studies demonstrated that H-RAS-V12 confers the metastatic potential in epithelial 
cells, whereas tropomyosin suppresses tumor growth and metastases. Thus, these data 
suggest that (i) TPM1 represents a convergent target of the synergism of RAS and TGF-β, 
and (ii) TGF-β-induced EMT is not sufficient for acquisition of invasive features, while 
activated RAS alters the TGF-β response and confers metastatic potential [52]. In this line, 
activation of RhoA through continuous stimulation of TGFBRI-ALK5 was required for efficient 
H-RAS-V12, V-RAF and V600E-BRAF mediated malignant transformation [53]. Smad3 was 
found to be critical for v-H-RAS-mediated transformation in murine embryonic fibroblasts 
through activation of Jun N-terminal kinase (JNK) and MAPK-ERK signaling [54]. In addition, 
Smad3 both suppressed and promoted a RASdriven cancer phenotype. Whereas expression 
of Smad3-dependent cytostatic genes of TGF-β1 were not altered by v-H-RAS along with an 
intact TGF-β1 growth arrest, expression of proteases and migration of keratinocytes was 
induced [55]. 
Smad Activation by Linker Phosphorylation 
Kretzschmar et al. described that the linker region of Smad2 and Smad3 is phosphorylated at 
several serine/threonine sites through growth factor-mediated MAPK-ERK activation which 
results in cytoplasmic retention of Smad2/Smad3 and attenuation of TGF-β signaling [56]. In 
contrast, Smad2/Smad3 with phosphorylated linker regions have been reported to be 
predominantly localized in the nucleus in invasive late-stage colorectal carcinoma [57,58]. 
Mutations of the Smad3 linker region preventing JNK-dependent phosphorylation resulted in 
a preserved tumor-suppressive function of TGF-β and inhibited tumor cell invasion. The 
distinct phosphorylation patterns of the Smad2/Smad3 linker region or C-terminal region 
were characterized using selective antibodies. TGFBRI-ALK5 and hepatocyte growth factor 
(HGF) induced JNK-dependent phosphorylation of Smad2 and Smad3 at the same sites in 
the linker region allowing their translocation into the nucleus together with Smad4 [59]. JNK 
inhibition reduced TGF-β or HGF-mediated cell invasion. However, TGF-β but not HGF 
treatment induced C-terminal Smad2/Smad3 phosphorylation, whereas HGF treatment 
reduced TGF-β-dependent elevation of p15Ink4B, which is mediated by Smad3 
phosphorylation at the C-terminal region. Other studies, however, have reported C-terminal 
phosphorylation of Smad2/Smad3 proteins in response to HGF and nocodazole, the latter 
mediated by the mitotic checkpoint kinase Mps1 in a TGF-β-independent fashion [60,61]. In 
colorectal cancer, Smad2/Smad3 is phosphorylated at C-terminal serine residues by 
TGFBRI-ALK5 while JNK and CDK4 differentially phosphorylated linker regions and Ctermini 
[62]. Dependent on CDK4, TGF-β generated pSmad2C/L (C/L, phosphorylation at C-
terminus and linker region) and pSmad3C/L, which enhanced cell growth by upregulation of 
c-MYC. TGFBRI-ALK5 signaling together with JNK stimulated cell invasion through 
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pSmad2L/C mediated matrix metalloproteinase (MMP)-9 expression. Clinical samples 
confirmed nuclear localization of pSmad2L/C and pSmad3L/C at the invasion front of TGF- 
β-producing, metastatic colon carcinomas. These data suggest that CDK4 together with JNK 
alters TGF-β signaling from tumor-suppressive to tumor-promoting at late stages of 
colorectal cancer. 
In the liver, tumor suppressive functions of TGF-β were mediated by pSmad3C 
(phosphorylation at C-terminus), while oncogenic activities such as cell proliferation and 
invasion were promoted by pSmad3L (phosphorylation at linker region) [63]. 
pSmad3Lmediated signaling induced ECM deposition by mesenchymal liver cells, and 
hepatitis B virus infected hepatocytes showed a transition from the anti-oncogenic pSmad3C 
to the fibrogenic/oncogenic pSmad3L pathway, accelerating liver fibrosis and increasing risk 
of HCC. Importantly, RAS-associated activation of JNK through pro-inflammatory cytokines 
such as interleukin-1β mediated this perturbed hepatocytic TGF-β signaling [64,65]. 
K-RAS and TGF-β signaling cooperated in the induction of SNAI1 (Snail), a transcriptional 
repressor of E-cadherin, in pancreatic cancer cells. This occured in a Smad-dependent 
manner independently of MAPK-ERK and JNK activation as well as in the absence of 
phosphorylation at the linker region of R-Smads [66]. SNAI1 also acts as a transcriptional 
repressor of RIN1, a RAB5 guanine nucleotide exchange factor (GEF), which downregulates 
receptor tyrosine kinases (RTKs) and promotes TGFBR signaling through enhanced 
endocytosis [67]. RIN1 integrates RAS and TGF-β signaling since persistent RTK-RAS 
activation stabilized TGF β/Smad induced SNAI1 protein by decreased glycogen synthase 
kinase (GSK)-3β, resulting in silencing of RIN1 and stabilization of RTKs by the concomitant 
reduction in RAB5-mediated TGFBR internalization. 
Smad-Independent Mechanisms 
R-RAS transformed EpH4 mammary epithelial cells were insensitive to TGF-β-mediated 
growth inhibition along with increased proliferation and malignancy in response to  
exogenous TGF-β. The effects of TGF-β were mediated through Smad-independent 
mechanisms and required the activation of TGF-β-associated kinase 1 (TAK1) and its 
downstream effectors JNK/p38MAPK/PI3K/AKT and mTOR pathways [68]. Independent of 
Co-Smad4, TGF-β signaling resulted in PI3K-mediated tyrosine phosphorylation of α-and β-
catenin leading to the dissociation of the E-cadherin/β-catenin complexes from actin 
cytoskeleton and reduced cell adhesion. Both PI3K and PTEN were associated with 
Ecadherin/ β-catenin complexes and TGF-β decreased the level of PTEN enhanced β-
catenin phosphorylation [69]. 
RAS Interferes with TGF-β/Smad at the Level of Transcription 
A mechanistic link between RAS, p53 and TGF-β has been demonstrated, as RAS-MAPK 
activity induced p53 N-terminal phosphorylation through CK1ε/δ enabling the interaction of 
Dissertation                                                                                                Michaela Petz 
 50   
p53 with TGF-β-activated Smads and promoting TGF-β-dependent cytostasis [70]. 
Interestingly, the growth-promoting effects of activated RAS are balanced by the wild type 
p53/Smad cooperation that sustains TGF-β growth control and thus limits neoplastic 
transformation. A more recent study in breast carcinoma showed insights into the enigma of 
the pro-metastatic switches of mutant-p53 and TGF-β by demonstrating that RAS-activated 
mutant-p53 and TGF-β cooperate to counteract the activity of the p53 family member p63. 
The p63 protein is a master regulator for maintaining normal epithelial stem cells by 
protecting them from apoptosis and coordinating their differentiation [71]. Noteworthy, 
oncogenic H-RAS/CK1ε/δ induced mutant-p53 phosphorylation and subsequent assembly of 
a mutant-p53/p63 protein complex in which Smads serve as essential platforms. Normal p63 
functions are antagonized within this ternary complex of mutant-p53/p63 and TGF-β 
activated Smads, allowing the gain of metastatic properties. In addition, Sharp1 and Cyclin 
G2 have been identified as metastasis suppressors that mediate p63 effects. Downregulation 
of Sharp1 and Cyclin G2 in response to the TGF-β/mutant-p53/p63 pathway promoted the 
pro-oncogenic and invasive TGF-β responses. These data provide novel insights into the 
mechanism of the interplay between RAS and TGF-β, since RAS signaling promotes mutant-
p53 phosphorylation and is required for the formation of the mutant-p53/Smad complex. RAS 
signaling is therefore suggested to play a significant regulatory role on the composition of co-
activators and co-repressors of Smad transcriptional complexes. 
RAS Interacts with the Activin and BMP Branches of the TGF-β Family 
A role in tumor development and progression has also been demonstrated for several other 
TGF-β family members including activin A, several BMPs, GDF15/MIC-1, and nodal, to name 
just some prominent examples. As described for most TGF-β family members, promotion or 
suppression of tumorigenesis mostly depends on the stage and type of tumor. For activin, an 
anti-oncogenic activity has been described in breast [72,73], colon [74] and HCC [75], 
whereas pro-oncogenic effects have been demonstrated in lung [76], prostate [77], 
esophageal cancer [78,79] and oral cancer [80]. 
Activin A uses a different set of receptors than TGF-β but depends on the same Smad 
proteins (Smad2/3/4) for most of its reported activities and relies on similar mechanisms for 
tumor suppression namely induction of apoptosis and cell cycle arrest via p15Ink4B [81,82]. 
Specific loss of activin signals in the course of tumor development has been connected to 
inactivating mutations of activin receptors in colon, pancreas, and prostate cancer [74,83,84] 
as well as overexpression of antagonistic proteins such as follistatin and follistatin-related 
gene (FLRG) in breast cancer and HCC [73,75]. In those malignancies with pro-tumorigenic 
roles of activin A, the signaling pathways are only beginning to be explored. Recently it has 
been shown that activin A, which inhibits growth and induces apoptosis in prostate cancer 
cell lines, is overexpressed and enhances cell migration in bone metastatis [77]. This 
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oncogenic effect was dependent on the interaction of Smad3 with androgen receptor (AR), 
demonstrating that activin A can switch to a tumor-promoting function similar to TGF-β 
depending on the stage of cancer progression. The activin antagonist follistatin suppressed 
metastasis in small cell lung cancer indicating a contribution of activin A to tumor 
dissemination [85]. In addition, ERK and p38MAPK-dependent signal transduction by activin 
A has been shown to be involved in the transcriptional control of Pit-1 and tyrosine 
hydroxylase [86,87]. In keratinocytes, activin induced stress fiber formation and migration in 
a Smad-independent fashion that includes RhoA and MEKK1 signaling resulting in 
phosphorylation of JNK and c-Jun [88]. This pathway was suggested to regulate epithelial 
morphogenesis and might contribute to pro-tumorigenic mechanisms of activin A. The RAS-
GAP binding protein Dok-1, which signals downstream of tyrosine kinase pathways, was 
found to act as an adaptor linking activin receptors with Smad3 and Smad4 activation [89]. 
Overexpression of Dok-1 enhanced activin-induced apoptosis and inhibited the RASERK 
pathway in a mouse B-cell line. As reported for TGF-β signal transduction, an impact of RAS-
MAPK-dependent phosphorylation in the Smad 2/3 linker region might also affect activin 
signaling, however, clear evidence needs to be demonstrated. A recent study on 
transcriptional cooperation showed that activin A increases vascular endothelial growth factor 
expression via a physical interaction of Smad2 with the MAPK-regulated transcription factor 
SP1 in HCC cell lines [90]. The synergistic cooperation of activin A with fibroblast growth 
factor (FGF)2, which mediates tube formation of bovine aortic endothelial cells, could be 
inhibited by follistatin, Smad7 or inhibition of ERK [91]. 
The cooperation of the Smad2/3-dependent activin/nodal pathway and RAS-MAPKactivating 
FGF2 signals including expression of Nanog was also required for maintaining pluripotency 
of human embryonic stem cells [92,93]. Since both the activin/nodal and the FGF/FGFR axis 
are hyperactivated in lung cancer and melanoma [76,94-96], it will be interesting to find 
possible implications of this cooperation on the stem cell-like properties of tumor cells. 
In contrast to TGF-β and activins, the BMP subfamily signals via the Smad1/5/8 of the 
canonical TGF-β pathway. Beside phosphorlylation at the C-terminus by ALK1/2/3/6, the 
linker region of Smad1 is phosphorylated by MAPKs (ERK, p38, JNK) as well as by GSK-3β 
[97-99], which has been connected to the inhibition of nuclear translocation and ubiquitin-
mediated degradation, thus reducing Smad transcriptional activity. In other studies, however, 
RAS-ERK signals enhanced the transcriptional activity of Smad1 in response to BMP [100]. 
Smad-independent activities of BMPs include signaling via direct interaction of the 
cytoplasmic tail of BMPRII with LIM kinase 1 (LIMK1), a regulator of actin dynamics, and 
suppression of PTEN via RAS-ERK signaling in Smad4-negative colon cancer cells 
[101,102]. With respect to the role of BMPs in tumor progression, the picture is diverse. 
Frequent inactivation of the BMP signaling pathway by mutation of BMP receptors or Smad 
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proteins was found in colon cancer [103,104]. In lung cancer, an association between RAS 
mutations and silencing of BMP expression has been demonstrated. NSCLC patients with K-
RAS codon 12 mutations were six times more likely to have epigenetically silenced 
BMP3b/GDF10 or BMP6 than those with wild type K-RAS [105]. The molecular mechanism 
behind this crosstalk, however, remains to be elucidated. BMP2 and BMP4 have been 
implicated in enhanced invasion and bone metastasis of breast cancer cells as well as in 
EMT of ovarian cancer cells [106,107]. BMP7 on the other hand has been demonstrated to 
counteract TGF-β1 induced EMT in renal tubular epithelial cells [108]. While induction of 
EMT by BMP4 was associated with Rho GTPase activation, inhibition of EMT by BMP7 
involved Smad1-mediated signal transduction. Thus, context-dependent modulation of BMP 
signals by the cell is crucial for functional outcomes. Future studies need to work out the 
mechanisms how RAS-dependent signals contribute to pro- versus anti-tumorigenic effects 
of BMP-activated Smad signals. 
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7.4. Implications for targeted cancer therapy 
Pathways of the RAS and TGF-β family are attractive targets for cancer therapy since they 
are activated in numerous carcinomas. Yet, the success of specifically targeting either RAS 
or TGF-β signaling has been limited due to the toxicity of drugs or to vast pleiotropic effects 
leading to physiological imbalances. As comprehensively outlined, experimental cancer 
research revealed that both RAS and TGF-β signaling pathways are promising targets to 
combat tumorigenesis, however, much remains to be investigated to understand the dual 
anti- and pro-oncogenic roles of TGF-β signaling and to develop proper anti-cancer concepts 
targeting TGF-β. Determination of deleterious or beneficial TGF-β signaling in cancer 
development and the complexity of the interrelationship between RAS and TGF-β signaling, 
which depends on the cell type, tumor stage and tissue context, complicates therapeutic 
interference with TGF-β signaling [109]. The aim of targeted therapy must be directed 
against the double-edge sword of TGF-β through inhibition of the pro-oncogenic aspects at 
advanced stages of cancer progression and the proper restoration of anti-oncogenic effects 
that are observed during early stages of tumor development. 
Various strategies have been pursued to accomplish inhibition of TGF-β signaling including 
(i) sequence-specific anti-sense oligonucleotides for degradation of TGF-β mRNA, (ii) 
isoform selective, neutralizing antibodies or soluble TGFBRII fragments blocking the binding 
of TGF-β ligands to the heteromeric receptor complex, and (iii) low molecular weight 
inhibitors antagonizing the intracellular kinase activity of TGFBRs [110-112]. For instance, 
the small molecule inhibitor LY2109761 targeting TGFBRI-ALK5 and TGFBRII induced a 
complete abrogation of Smad-dependent and - independent signaling in human colon 
carcinoma cells harboring activated K-RAS, resulting in reduced tumor cell invasion and liver 
metastasis [113]. Remarkably, TGF-β antisense approaches showed reactivation of tumor-
specific immune responses, rendering patients more susceptible to a number of different 
therapeutic measures [110]. Inhibitors in clinical settings such as human monoclonal 
antibodies against TGF-β2 (CAT-152) and TGF-β1 (CAT-192) successfully completed phase 
I/II trials. A TGF-β2 antisense oligonucleotide (AP 12009) has begun phase II/III testing to 
treat high grade gliomas and phase I/II trials against pancreatic cancer. However, these 
approaches in clinical trials focus on the inhibition of non-canonical and canonical TGF-β 
signaling rather than on the molecular crosstalk between TGF-β signaling and the RAS 
pathway. Recent strategies further involve targeting of TGF-β signaling in the tumor 
microenvironment, and in particular, the immune system which is critical for carcinoma 
progression. Importantly, TGF-β provided by bone marrow-derived Gr-1+CD11b+ immature 
myeloid cells interfered with the immune system by suppression of natural killer cells, 
cytotoxic T cell and B cell function [28,114]. Infiltration of Gr-1+CD11b+ into breast 
carcinoma resulted in increased MMP and TGF-β production enforcing tumor cell invasion 
Dissertation                                                                                                Michaela Petz 
 54   
and metastasis [114]. Thus, Gr-1+CD11b+ cells act as an additional component causing the 
switch from tumor-suppressive to tumor-promoting functions which is of paramount 
importance for the timing of therapeutic TGF-β intervention. Recent studies suggested Gr-
1+CD11b+ cells as biomarkers for patient selection in ongoing phase I/II clinical trials of 
TGF-β therapy which is supported by recent findings in HCC and colorectal cancer 
[26,115,116]. 
Efforts to target hyperactive RAS (H-RAS, N-RAS or K-RAS) signaling emanating from 
mutations by employing GTP analogues or inhibitors of post-translational modifications such 
as farnesylation failed to prove successful so far [117]. However, inhibition of RTKs upstream 
of RAS like EGF-R or ErbB2/Her2 is successfully used in the clinic in selected malignancies 
and patient collectives [118]. Moreover, inhibition of downstream effectors of RAS like RAF 
and MEK is currently being tested in clinical trials [119]. Recent studies showed that NF-κB, 
which is a master regulator of the inflammatory response, might be a more promising target 
for interfering with cancer development than RAS itself [120]. TBK1, activated by the RAS-
RAL pathway and inducing NF-κB by phosphorylation of IκB (an inhibitor of NF-κB), has 
been described to be essential for mutated RAS signaling [121,122]. Targeting of NF-κB 
might be particularly promising, since RAS and TGF-β together induce NF-κB signaling 
associated with EMT and metastasis of mammary epithelial cells in vivo, which is reversible 
by NF-κB inhibition [123]. This therapeutic approach would favor the interference with the 
deleterious consequences of the RAS-TGF-β cooperation by the concomitant maintenance 
of tumor-suppressive TGF-β functions. 
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7.5. Concluding remarks 
TGF-β family, which is fundamentally involved in tumor progression. It seems, however, that 
most carcinomas are not addicted to the oncogenic activity of RAS as its abatement by 
pharmacological intervention is insufficient to combat the disease. Yet, RAS activation with 
respect to its crosstalk with TGF-β and the concomitant onset of the pro-oncogenic aspects 
of the TGF-β family appears to comprehensively overcome physiological programs and to 
induce a state of cellular amnesia [124]. This state of cellular amnesia rather than addiction 
to a single oncogene like RAS results in bypassing checkpoint mechanisms which is 
essential for (i) EMT, cell invasion and metastasis (ii) immune suppression, (iii) 
neoangiogenesis, (iv) multiple drug resistance, and (v) self-renewal and cancer stemness 
during carcinoma progression. Pharmacological interference with TGF-β signaling and its 
modulation by RAS activation could be most effective, when it succeeds in targeting the pro-
oncogenic aspects by simultaneously restoring the anti-oncogenic functions of TGF-β. Thus, 
future studies should focus on targeting the ambiguous role of TGF-β signaling in carcinoma 
progression, and should take combination therapy with inhibition of RTK-RAS signaling into 
consideration. 
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7.7. Abbreviations 
ActRII  activin type II receptor 
ActRIIB  activin type IIB receptor 
ALK   activin receptor-like kinase 
AMH   anti-Muellerian hormone 
AMHRII  anti-Mullerian hormone type II receptor 
AR   androgen recptor 
ARE   activin response element 
BMP   bone morphogenic protein 
BMPRII  BMP type II receptor 
BRE   BMP response element 
CDK   cyclin-dependet kinase 
CDKI   cyclin-dependet kinase CDK inhibitor 
Co-Smad  common mediator Smad 
Dok-1   docking protein 1 
ECM   extracellular matrix 
EGF   epidermal growth factor 
EGF-R  epidermal growth factor receptor 
EMT   epithelial to mesenchymal transition 
ERK   extracellular regulated kinase 
FGF   fibroblast growth factor 
FLRG   follistatin-related gene 
FOXH1  forkhead box H1 
GDF   growth and differentiation factor 
GEF   guanine nucleotide exchange factor 
GSK-3β  glycogen synthase kinase 3β 
HCC   hepatocellular carcinoma 
HGF   hepatocyte growth factor 
H-RAS  Harvey rat sarcoma viral oncogene homolog 
ID   inhibitor of differentiation 
I-Smad  inhibitory Smad 
JNK   c-Jun N-terminal kinase 
K-RAS  Kirsten rat sarcoma viral oncogene homolog 
LIMK1  LIM kinase 1 
MAPK  mitogen activated protein kinase 
MDCK  Madin-Darby canine kidney cells 
MEK   mitogen activated protein kinase kinase 
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MH   Mad homology 
MMP   matrix metalloprotease 
Mps1   monopolar spindle 1 
NADPH  nicotinamide adenine dinucleotide phosphate 
NF-κB  nuclear factor κB 
NLS   nuclear localization signal 
N-RAS  neuroblastoma RAS viral oncogene homolog 
NSCLC  non-small lung cell carcinoma 
PDGF   platelet-derived growth factor 
PI3K   phosphatidyl-inositol-3 kinase 
PKB   protein kinase B 
PLCε   phosholipase Cε 
PTEN   phosphatase and tensin homolog 
RAF   rat sarcoma activated factor 
RAS   rat sarcoma 
RASSF  RAS association domain containing family 
RIN1   RAS interaction protein 1 
R-Ras  related RAS viral oncogene 
R-Smad  receptor-regulated Smad 
RTK   receptor tyrosine kinase 
TAK1   TGF-β associated kinase 1 
TGFBRI  TGF-β type I receptor 
TGFBRII  TGF-β type II receptor 
TGF-β  transforming growth factor β 
TIAM1  T cell lymphoma invasion and metastasis 1 
TPM1   tropomyosin 1 
TRAF6  tumor necrosis factor receptor-associated factor 6 
v-RAS  rat sarcoma viral oncogene 
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7.9. Figures 
 
Figure 1 
Collaboration between RAS signaling and the TGF-β/activin/BMP pathways. Upon binding of 
cytokines of the TGF-β/activin/BMP family to TGF-β/activin/BMP-specific type II receptors, 
heterodimerization with type I receptors of activin receptor-like kinases (ALKs) occurs. Type I 
receptors further phosphorylate receptor-regulated (R)-Smads (Smad1, Smad2, Smad3, 
Smad5 and Smad8) and cause their nuclear translocation together with the common-partner 
(Co-) Smad4. In the nucleus, Smad complexes bind to their respective response elements in 
target gene promoters and act as transcription factors which modulate gene expression. 
TGF-β/activin/BMP signaling is controlled at the level of (i) ligand mobilization and binding, 
(ii) receptor heterodimerization and activation, (iii) phosphorylation of R-Smads and nuclear 
shuttling of R/Co-Smad as well as (iv) Smaddependent transcription complexes. The 
crosstalk of RAS and TGF-β family proteins involves (i) modulation of RAS subeffector 
proteins by TGF-β family receptors, and (ii) the interference of RAS signaling components 
either with the activation and nuclear translocation of Smad effectors or with Smad-
dependent regulation of transcription. 
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Figure 2 
Schematic domain structure and phosphorylation pattern of Smad proteins. Smads consist of 
the N-terminal Mad-homology (MH) 1 region and the C-terminal MH2 domain which is joined 
by the linker region. The MH1 region is required for DNA-binding and contains a nuclear lo-
calization signal (NLS), whereas the MH2 region is involved in protein-protein interactions 
required for regulation of transcription. In Smad2, direct binding of DNA is blocked by an ad-
ditional sequence in the MH1 domain. ALK1-7 phosphorylate R-Smads at the two serine res-
idues of the C-terminal SXS motif, which generally leads to heterooligomerization with 
Smad4 and nuclear translocation. Several RAS-regulated kinases such as ERK, JNK and 
p38MAPK phosphorylate Smad proteins predominantly in the linker region and modulate 
their activity. 
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8.1. Abstract 
The majority of transcripts that harbor an internal ribosome entry site (IRES) are involved in 
cancer development via corresponding proteins. A crucial event in tumor progression 
referred to as epithelial to mesenchymal transition (EMT) allows carcinoma cells to acquire 
invasive properties. The translational activation of the extracellular matrix component laminin 
B1 (LamB1) during EMT has been recently reported suggesting an IRES-mediated 
mechanism. In this study, the IRES activity of LamB1 was determined by independent 
bicistronic reporter assays. Strong evidences exclude an impact of cryptic promoter or splice 
sites on IRES-driven translation of LamB1. Furthermore, no other LamB1 mRNA species 
arising from alternative transcription start sites or polyadenylation signals were detected that 
account for its translational control. Mapping of the LamB1 5’-untranslated region (UTR) 
revealed the minimal LamB1 IRES motif between -293 to -1 upstream of the start codon. 
Notably, RNA affinity purification showed that the La protein interacts with the LamB1 IRES. 
This interaction and its regulation during EMT were confirmed by ribonucleoprotein 
immunoprecipitation. In addition, La was able to positively modulate LamB1 IRES translation. 
In summary, these data indicate that the LamB1 IRES is activated by binding to La which 
leads to translational upregulation during hepatocellular EMT. 
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8.2. Introduction 
The interaction of tumor cells with the extracellular matrix (ECM) is essential for cancer 
invasion and metastasis. Laminins constitute the ECM as the main non-collagenous 
glycoproteins of the basement membrane and affect the migratory behavior of a variety of 
malignant cell types [4]. Laminin B1 (LamB1) represents one moiety of the three β-subunits 
that assemble with α- and γ-chains to form a multitude of heterotrimeric laminin isoforms [5]. 
LamB1 modulates laminin-mediated integrin signaling that promotes cell adhesion, motility 
and differentiation [6]. In addition, LamB1 is the ligand of the monomeric 67 kDa laminin 
receptor (LamR; [7-9]) that drives tumor cell invasion as well as angiogenesis and is strongly 
expressed in many metastatic cancers [10-12]. The overexpression of LamB1 has been 
particularly reported in hepatocellular carcinoma (HCC), which is frequently preceded by 
fibrosis and cirrhosis and thus accompanied by increased ECM deposition. Accordingly, 
LamB1 expression is augmented during transforming growth factor (TGF)-β induced liver 
fibrosis of transgenic mice [13]. Proteome analysis of HCC patients revealed a rise of LamB1 
levels in cirrhotic tissue and a further increase in carcinoma cells [14]. The elevated LamB1 
expression in HCC associates with upregulation of β1 integrin and LamR [15-17].  
A crucial event in tumor progression is the gain of invasive properties of carcinoma cells by 
epithelial to mesenchymal transition (EMT). This process is characterized by the loss of 
epithelial cell polarity and acquisition of a fibroblastoid phenotype enabling tumor cells to 
leave epithelial cell organisation [18]. In HCC cells, EMT can be induced by the synergy of 
TGF-β and oncogenic Ras signaling, which are frequently activated in HCC patients [18-21]. 
Recently, we showed that LamB1 is translationally upregulated in HCC cells that have 
undergone EMT through the cooperation of TGF-β with Ras [22]. The translational activation 
of LamB1 was proposed to be regulated by an internal ribosome entry site (IRES). 
The IRES secondary structure located within the 5’-untranslated region (UTR) of the mRNA 
allows direct ribosome binding and translation initiation independently of the cap structure. 
Translation of key regulatory proteins that are involved in cancer- relevant processes such as 
angiogenesis, mitosis and apoptosis is frequently driven by internal initiation [23]. IRES-
translated transcripts escape from downregulation of cap-dependent protein synthesis and 
foster tumor cells to overcome stress conditions induced by hypoxia or nutrient deprivation 
[24]. Deregulation of translation control affects IRES-mediated translation in a dual way. Cap-
dependent translation of IRES-competent transcripts is increased in the presence of high 
levels of activated translation initiation factor eIF4E, while same transcripts are translated by 
IRES-dependent mechanism when eIF4E is downregulated in response to cellular stress or 
other stimuli [25, 26]. Furthermore, IRES-mediated translation is regulated by IRES 
transacting factors (ITAFs) which mainly comprise heterogeneous nuclear ribonucleoproteins 
(hnRNPs) that shuttle between cytoplasm and nucleus [27]. ITAFs selectively bind IRES 
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structures and modulate their activity, allowing a distinguished response of IRES transcripts 
to cellular conditions that affect translation. A role of ITAFs in regulating cell survival and 
angiogenesis has been described although little is known about tumor-associated alterations 
of ITAFs [28]. 
Here we demonstrate that the 5’-UTR of LamB1 harbors a bona fide IRES structure localized 
between -293 to -1 upstream of the start codon. RNA affinity purification as well as in vivo UV 
crosslinking combined with RNP immunoprecipitation allowed the identification of La protein 
as an ITAF that binds to the LamB1 IRES. Moreover, La was found to positively regulate the 
LamB1 IRES activity which might account for the increased IRES mediated LamB1 
translation of EMT-transformed hepatocytes. 
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8.3. Material and Methods 
Construction of the plasmids 
The LamB1 5’-UTR was cloned downstream of the Firefly luciferase open reading frame 
(ORF) into p-F resulting in pLam-F[22]. Primer were designed according to GenBank 
sequence NM_002291. Plasmids for the cryptic promoter assay were generated by removal 
of the CMV promoter from pF, pLam-F and pEMCV-F [22]. Bicistronic plasmids were 
constructed based on the pβgal/5’(-162)/CAT vector (a kind gift from Dr. Martin Holcik) [29]. 
The XIAP IRES sequence was removed from pβgal/5’(-162)/CAT to generate the empty 
control vector pβgal/CAT, or replaced by the LamB1 5’-UTR resulting in pβgal/Lam/CAT. 
Deletion fragments for the mapping of the 5’-UTR were amplified by PCR and cloned into 
pβgal/CAT. Primer sequences are shown in Supplementary Table S1. Plasmids for the 
streptavidin-tethered RNA affinity purification were generated by inserting the LamB1 5’-UTR 
or the minimal XIAP IRES sequence into the pTrap vector (kindly provided by Dr. Martin 
Dienstbier) [30]. Primer sequences are shown in Supplementary Table S2. 
Cell culture 
Immortalized murine MIM-1-4 hepatocytes were grown on collagen-coated culture dishes in 
RPMI 1640 plus 10% fetal calf serum (FCS), 40 ng/ml human TGF-α (Sigma, St.Louis, USA), 
30 ng/ml human insulin-like growth factor II (IGF-II, Sigma, St.Louis, USA), 1.4 nM insulin 
(Sigma, St.Louis, USA) and antibiotics, as described previously [31]. Malignant epithelial 
MIM-R hepatocytes are derived from MIM-1-4 cells by expressing oncogenic Ha-Ras and 
green fluorescent protein as outlined recently [32]. TGF-β1 (R&D Systems, Minneapolis, 
USA) was used at a concentration of 2.5 ng/ml for the first 72 hours of EMT induction. For 
long-term treatment of MIM-R hepatocytes, TGF-β1 was supplemented to the medium at a 
concentration of 1 ng/ml, resulting in fibroblastoid MIM-RT cells after more than two weeks. 
Human SW480 and HEK293 cells were cultured in DMEM and HepG2 cells in MNP each 
plus 10% FCS. The human HCC cell lines Hep3B and AKH3p were grown in RPMI 1640 
medium supplemented with 10% FCS. All cells were kept at 37°C and 5% CO2 and routinely 
screened for the absence of mycoplasma. 
Western blot analysis 
The preparation of cellular extracts, separation of proteins by SDS polyacrylamide gel 
electrophoresis and immunoblotting were performed as described recently [21]. Cytoplasmic 
and nuclear cell fractions were generated using a Proteo-JET® kit (Fermentas, St.Leon-Rot, 
Germany) according to the manufacturers description. 30 µg protein extract was loaded onto 
gels and immunological detection of proteins was performed with the Super Signal detection 
system (Pierce Chemical Company, Rockford, USA). The following primary antibodies were 
used: anti-laminin B1 (Neo Markers, Fremont, USA), 1:1.000; anti-hnRNP A1 (Santa Cruz 
Biotechnology, California, USA), 1:1.000; anti-actin (Sigma, St. Louis, USA), 1:2.000; anti-La 
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(Santa Cruz Biotechnology, California, USA) and (Cell Signaling, MA, USA), 1:1.000; anti-
tubulin (Sigma, St. Louis, USA), 1:1.000; anti-nucleoporin (BD Biosciences, NJ, USA), 
1:1.000. Secondary antibodies (Calbiochem, LaJolla, USA) were used at dilutions of 
1:10.000. 
Reverse transcriptase (RT)-polymerase chain reaction (PCR), quantitative (q)PCR and 
RACE-PCR 
RNA was extracted, DNaseI treated and reverse transcribed using a RNA isolation and 
cDNA synthesis kit (Quiagen, Hilden, Germany) as recommended by the manufacturer. 
Aliquotes of the cDNA were employed for RT-PCR using Ready-To-Go PCR beads 
(Amersham, Uppsala, Sweden). Amplification products of semiquantitative PCR were 
visualized by ethidium bromide staining on a 1% agarose gel. Primer sequences are shown 
in Supplementary Table S3. qPCR was performed with Fast SYBR green (Applied 
Biosystems, CA, USA) according to the recommendations of the manufacturer and quantified 
with the 7500 Fast Real Time PCR System (Applied Biosystems). Primer sequences are 
shown in Supplementary Table S4. 5’ and 3’ RACE-PCR was performed using a First 
Choice® RLM-RACE Kit (Applied Biosystems, CA, USA) according to the manufacturer’s 
recommendation. Primer sequences are shown in Supplementary Table S5. 
Transient transfection and reporter assays 
Cells were plated on 6-well plates and transiently transfected after 24 hours with 
Lipofectamine Plus as recommended by the manufacturer (Invitrogen, Carlsbad, USA). Cells 
were lysed 48 hours post transfection and enzymatic reporter activities were determined. 
Luciferase activity was measured with a Luminoskan microplate reader (Labsystems, 
Farnborough, UK) as recently described [22]. β-galactosidase (β-gal) activity was 
photometrically determined using o-nitrophenyl-β-d-galactopyranoside and chloramphenicol 
acetyltransferase (CAT) activity was measured by ELISA (Roche, Mannheim, Germany) as 
recommended by the manufacturer. In assays analyzing the interference of cap-dependent 
translation, reporter activities were normalized to mRNA levels as quantified by qPCR. 
Otherwise, relative IRES activity of bicistronic assays was calculated as the ratio of CAT/β-
gal. Luciferase activities of monocistonic vectors were normalized to β-gal activities of a co-
transfected β-gal reporter [22]. Assays were performed in triplicate and results represent the 
average of three independent experiments. 
RNA-protein immunoprecipitation 
Cells were transfected with a bicistronic vector as described above or directly UV crosslinked 
with 400 mJ/cm2 before cell lysis. Lysates were centrifuged at 1200 g and supernatants were 
aliquoted corresponding to 3x106 cells. 5 µg La antibody (Santa Cruz Biotechnology, 
California, USA) were crosslinked to 50 µl Dynabeads® Protein A (Invitogen, California, 
USA) using Bis(sulfosuccinimidyl)suberate (BS3; Thermo Fisher Scientific, Massachusetts, 
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USA) as described by the manufacturer. Crosslinked Dynabeads® were incubated with 
aliquots of precleared cell lysates at room temperature, washed and the immunoprecipitated 
RNA-protein complexes were eluted at 95°C. Eluates were treated with proteinase K 
(Fermentas, St.Leon-Rot, Germany) and the RNA was ethanol-precipitated after extraction 
with phenol-chloroform. After treatment with DNaseI (Fermentas), mRNA was purified using 
a mRNA isolation kit (Roche, Mannheim, Germany) and subjected to cDNA synthesis. 
Subsequent RT-PCR or qPCR was performed as described above. To determine the amount 
of input RNA that was used for immunoprecipitation, RNA was isolated from aliquots of cell 
lysates using a RNA isolation kit (Quiagen, Hilden, Germany), treated with proteinase K and 
processed as described above. The buffer for cell lysis and immunoprecipitation consisted of 
30 mM HEPES pH 7.3, 160 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 0.1% NP-40, 0.5% Triton X-
100 and 10% glycerol. The washing buffer included PBS pH 7.4 and 0.02% Tween. The 
elution buffer was composed of 100 mM Tris/HCl pH 7.4, 5% SDS, 70 mM β-
mercaptoethanol and 5 mM DTT.  
Northern blot analysis 
Cells were grown on a 6 cm culture dish and transfected with bicistronic vectors using 
Lipofectamine Plus as recommended by the manufacturer (Invitrogen, Carlsbad, USA). 
mRNA was isolated with a mRNA isolation kit (Roche, Mannheim, Germany). RNA samples 
were heated at 65°C for 15 minutes in RNA sample buffer, cooled on ice and separated on a 
MOPS-formaldehyde agarose gel. RNA was transferred to a membrane (NEN life science 
products, MA, USA) and UV crosslinked. Probes were amplified by PCR from the 
pβgal/Lam/CAT vector in the presence of 32P-labeled dCTP. Primer sequences are 
described in Supplementary Table S6. Unincorporated nucleotides were removed using a 
Gelextraction Kit (Quiagen, Hilden, Germany). Membranes were prehybridized for 4 hours 
and then hybridized over night at 42°C with 5x107 cpm of radiolabelled probe. Membranes 
were washed at 65°C and exposed to x-ray films at -80°C.   
In vitro translation  
Bicistronic vectors containing the LamB1 5’-UTR or XIAP IRES were in vitro transcribed 
using a MEGAshortscript® kit (Applied Biosystems, CA, USA). Rabbit reticulocyte lysate 
(Promega, Madison, USA) was programmed with the transcripts and in vitro translation was 
performed according to the guidelines of the manufacturer. CAT activities were determined 
by ELISA (Roche, Mannheim, Germany) and normalized to transcript levels quantified by 
CAT RT-PCR. In order to preclear the reticulocyte lysate from La, 5 µg La antibody was 
crosslinked to 50 µl Dynabeads® Protein A (Invitogen, California, USA) by using BS3 as 
described by the manufacturer (Thermo Fisher Scientific, Massachusetts, USA). Reticulocyte 
lysate was incubated with crosslinked Dynabeads® for 30 min at room temperature followed 
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by removal of Dynabeads®. 1 µg of recombinant La (Prospec, Rehovot, Israel) was added to 
reconstitute La activity. Results show the average of three independent experiments.  
Streptavidin-tethered RNA affinity purification 
2x107 cells were lysed and precleared with 50 µl streptavidin-linked magnetic beads (Sigma, 
St. Louis, USA). Another 50 µl of magnetic beads were washed and resuspended in 200 µl 
buffer. 5 µg of in vitro transcribed S1-aptamer fused RNA and 5 µl RNasin (Promega, 
Madison, USA) were added and the beads were incubated on a thermomixer for 90 minutes 
at 4°C with moderate shaking. RNA-associated beads were washed with 200 µl buffer and 
further incubated with the precleared protein extract on a thermomixer for 90 min at 4°C 
whilst shaking. Beads were then washed 5 times with buffer. RNA-protein complexes were 
eluted by incubating with buffer containing biotin at a final concentration of 10 mM at 4°C for 
160 minutes. Eluted proteins were analyzed by SDS polyacrylamide gel electrophoresis 
followed by silver staining or Western blot. The buffer used for cell lysis, affinity 
chromatography, washing and elution contained 30 mM HEPES pH 7.3, 160 mM KCl, 2.5 
mM MgCl2, 1 mM DTT, 0.1% NP-40, 0.5% Triton X-100 and 10% glycerol. 
Stable knock-down of La 
MISSION® shRNA lentiviral transduction particles (Sigma, St. Louis, USA) were used to 
knock-down La (NM_009278) in MIM-R and MIM-RT hepatocytes. Cells were transduced 
with viral particles containing shRNA against La (TRCN0000071284, TRCN0000071287) or 
non-target shRNA (SHC002V) in a pLKO.1 vector and treated with puromycine (5 µg/ml) for 
selection. 
Statistical analysis 
Data were expressed as means ± standard deviation (SD). The statistical significance of 
differences was evaluated using a paired, non-parametric Student’s t-test. Significant 
differences between experimental groups were * p<0,05, ** p<0,01 or *** p<0,005. 
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8.4. Results 
LamB1 mRNA in cancer cells 
Recently we identified the cap-independent translational upregulation of LamB1 during TGF-
β-induced EMT of epithelial MIM-R hepatocytes to invasive, fibroblastoid MIM-RT cells [22]. 
To further assess translational control of LamB1 during EMT, we studied a conceivable 
impact of LamB1 mRNA isoforms. Differential utilization of transcripts generated by e.g. 
alternative splicing is known to cause aberrant gene expression during oncogenesis [33]. 
Notably, the LamB1 5’-UTR sequence published in NCBI (NM_002291.2) is not entirely 
supported by expressed sequence tags (ESTs) or full length cDNA. Rather, the EST 
database dbEST contains transcripts that start at -147 nts or further downstream and fail to 
confirm the region from -335 to -154 in the 5’-UTR. In silico analysis of the 5’-UTR using 
Zuckers mfold version 4.11 predicted a strong secondary structure with a minimal free 
energy of -154 kcal/mol which could account for insufficient amplification and could explain 
missing ESTs [34, 35]. Therefore, we tested whether the first 1-181 nts of the published 
sequence were amplified from DNA contaminations. Interestingly, RT-PCR analysis of 
different human cell lines after DNase treatment showed amplification of the entire 5’-UTR 
sequence comprising 335 nts as published in NCBI (Figure 1A). Combined DNase and 
RNase treatment failed to show amplicons, excluding the presence of DNA. Thus, our data 
confirm the expression of the published human LamB1 5’-UTR sequence. 
Furthermore, we performed RACE-PCR of the 5’- and 3’-UTR to identify any transcript 
variants that may be involved in translational regulation of LamB1 (Figure 1B). In 
accordance, we were able to amplify a single 335 nts long 5’-UTR sequence in various 
human cancer cell lines. No other transcripts were detected suggesting the absence of 
alternative splice products of the LamB1 5’-UTR. In addition, we analyzed variations in the 
LamB1 3’-UTR since shortening of the 3’-UTR by alternative cleavage or polyadenylation 
was demonstrated to be involved in translational activation of oncogenes [36]. RACE-PCR of 
the 3’-UTR resulted in a single amplicon of 135 nts, indicating that the LamB1 3’-UTR is not 
altered in tumorigenesis. Consistently, LamB1 Northern blot analysis of two human tumor cell 
lines displayed single transcripts (Figure 1C). Together, these data suggest that translation of 
LamB1 is not regulated by alternative 5’-UTR species or shortening of the 3’-UTR. 
Translational activation of LamB1 is IRES mediated in EMT-transformed cells 
We recently showed that the LamB1 5’-UTR directs translation of a bicistronic transcript 
when inserted in the intercistronic region of a vector containing Renilla and Firefly luciferase 
reporters [22]. Although this bicistronic vector is widely used there have been issues with 
false positive signals derived by alternative splicing [37, 38]. Furthermore, it has been 
described that intensities of IRES activities can strongly vary depending on the type of 
bicistronic reporters [39, 40]. Therefore we employed an alternative bicistronic vector 
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encoding β-galactosidase (β-gal) as upstream and chloramphenicol acetyltransferase (CAT) 
as downstream reporter [37]. The LamB1 5’-UTR was inserted into the intercistronic region 
and the empty vector served as negative control (Figure 2A). Since the cellular IRES of X 
linked inhibitor of apoptosis (XIAP) and its ITAFs are well documented, the minimal XIAP 
IRES sequence was utilized as positive control [29, 41, 42]. Human SW480 colon carcinoma 
cells were transfected with bicistronic vectors and β-gal and CAT activities were determined 
(Figure 2B). Reporter activities were normalized to mRNA levels quantified by qPCR, and 
thus display the ratio of active protein to bicistronic transcript levels allowing conclusions on 
translation efficiencies. These data show an about 7-fold increase of LamB1 IRES-mediated 
CAT translation as compared to control. Figure 2C normalizes CAT to cap-dependent β-gal 
translation rates of the bicistronic transcripts, indicating a more than 6-fold upregulation of 
LamB1 IRES activity. These data corroborate our recent findings and demonstrate that the 
LamB1 5’-UTR mediates cap-independent translation in two independent bicistronic reporter 
systems [22].  
We next analyzed whether the IRES activity of LamB1 is regulated upon hepatocellular EMT 
by employing bicistronic experiments in immortalized MIM-1-4 hepatocytes, malignant 
epithelial MIM-R hepatocytes that were transformed with oncogenic Ras as well as in those 
that have undergone EMT upon TGF-β treatment (MIM-RT). All cells were transfected with 
bicistronic constructs containing either the LamB1 5’-UTR, the minimal XIAP IRES or the 
empty vector. β-gal (Figure 2D) or CAT activities (Figure 2E) were normalized to transcript 
levels and displayed as the ratio of IRES- to cap-dependent translation (Figure 2F). As 
expected, β-gal levels displayed no significant variations of cap-dependent translation rates 
in the cell lines (Figure 2D). CAT activities were 2.7-fold elevated in EMT-transformed MIM-
RT hepatocytes as compared to epithelial MIM-R cells (Figure 2E), suggesting activation of 
LamB1 IRES translation upon hepatocellular EMT. Normalization of β-gal to CAT activities as 
shown in Figure 2F revealed comparable data as depicted in Figure 2E. These results are 
consistent with recently published data that were obtained using Renilla and Firefly luciferase 
reporters [22]. Notably, LamB1 IRES translation showed higher levels than XIAP in the 
malignant progression of hepatocytes (Figure 2E and 2F). This effect might be cell type 
specific since LamB1 and XIAP exhibited similar activities in SW480 colon cancer cells 
(Figure 2C). Together, these data show that the LamB1 5’-UTR confers translation of the 
downstream cistron in the β-gal/CAT constructs, indicating IRES-mediated translation. 
Furthermore, LamB1-driven IRES translation in this assay is activated upon hepatocellular 
EMT which corroborates recent data [22]. 
The LamB1 5’-UTR does not direct aberrant transcription or cryptic splicing  
Bicistronic assays to determine IRES activity have been criticized since reporter activity of 
the downstream cistron may arise from the presence of cryptic promoter or splice sites within 
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the 5’-UTR rather than from the IRES. In order to detect any aberrant bicistronic transcripts, 
we performed Northern blot analysis of SW480 and MIM-R cells transfected with the 
bicistronic vector containing LamB1 5’-UTR or empty control. Probes for the β-gal and CAT 
reporter hybridized to the bicistronic mRNA revealed single transcripts of equal size (Figure 
3A). Truncated mRNAs generated from cryptic promoter or splice sites could not be 
detected. As Northern blot analysis could fail to detect smaller transcripts due to limited 
sensitivity, we determined the ratio of CAT to β-gal cistrons by qPCR. This analysis revealed 
that ratios were comparable between bicistronic vectors containing either XIAP IRES, LamB1 
5’-UTR or empty control (Figure 3B). These data indicate that the LamB1 5’-UTR does not 
direct aberrant transcription or splicing.  
To further analyze cryptic promoter activity, we constructed vectors containing the LamB1 5’-
UTR, the EMCV IRES or the empty control upstream of a Firefly luciferase reporter, each in 
presence or absence of a CMV promoter. These vectors were transfected into MIM-R 
hepatocytes together with a β-gal reporter plasmid and Firefly activities were normalized to β-
gal levels (Figure 3C). Interestingly, promoterless plasmids showed residual luciferase 
activities of 6-8%. However, these remaining activities are considered to be independent of 
the sequence upstream of the luciferase reporter, since they were almost equally detected in 
vectors under investigation. These results suggest that cryptic transcription occurs within the 
Firefly luciferase, which has already been reported [43]. To identify the origin of the aberrant 
transcription, we performed RT-PCR using primer that bind within the LamB1 5’-UTR (A,B,C) 
or within the Firefly luciferase open reading frame (D,E,F; Figure 3D). To exclude DNA 
contaminations RNA extracts were treated with RNase resulting in no amplicon. Only primer 
located within the Firefly luciferase (E,F) amplified transcripts of promoterless vectors in 
presence or absence of the LamB1 5’-UTR, suggesting a cryptic promoter activity within the 
Firefly luciferase rather than in the LamB1 5’-UTR. These data provide strong evidence that 
the LamB1 5’-UTR does not drive aberrant transcription and that translation of the bicistronic 
vector containing the LamB1 5’-UTR was indeed mediated by an IRES. 
Determination of the minimal LamB1 IRES motif 
To determine the minimal cis-acting IRES motif of the LamB1 5’-UTR, we generated 
bicistronic constructs containing deleted fragments of the 5’-UTR (Figure 4). The sequence 
was truncated in steps of 50 nts starting from the 5’ or 3’-end. MIM-R and MIM-RT 
hepatocytes were transfected with the constructs and CAT activities were normalized to β-gal 
levels. The segment between -293 to -1 upstream of the start codon retained full IRES 
activity, while the region between -241 to -1 showed reduced IRES activity indicating that the 
minimal IRES motif starts within -293 and -241. A sequence upstream of the start codon 
containing 82 nts (-82 to -1) displayed 31% activity of the full length 5’-UTR and therefore 
might have still some ability to attract the translation initiation complex. Deletion of this region 
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caused a reduced activity of the remaining fragment (-335 to -82) to 64% of the full length 5’-
UTR, suggesting that it is not essential for internal ribosome binding but may work as an 
enhancer of IRES activity. Furthermore, a motif that regulates IRES activity in response to 
TGF-β induced EMT might start within -241 to -180, since the -241 to -1 fragment is still 
regulated between MIM-R and MIM-RT cells while 5’-deletion to -180 nts results in similar 
IRES activities in both cell lines. Taken together these data reveal a minimal IRES motif 
required for translational activity that starts between -293 to -241 and ends between -82 and 
-1, and in addition, suggest an IRES domain between -241 to -180 that responds to TGF-β. 
La interacts with the LamB1 5’-UTR in vitro and in vivo 
IRES-driven translation has been shown to be regulated by ITAFs [27]. Therefore, we aimed 
to identify RNA binding proteins that interact with the LamB1 5’-UTR by streptavidin-tethered 
RNA affinity purification. Constructs containing the LamB1 5’-UTR or the minimal XIAP IRES 
downstream of two S1 aptamers were generated. The minimal XIAP IRES was applied as 
control for selectivity since several interacting ITAFs have already been described [41, 42, 
44]. The constructs were in vitro transcribed and RNA was conjugated to magnetic 
streptavidin beads. Whole protein extracts of HEK293 cells were incubated with either 
streptavidin beads alone, streptavidin beads conjugated to the transcript of the LamB1 5’-
UTR or streptavidin beads conjugated to the XIAP transcript. Elution with biotin allowed a 
high selectivity for RNA associated proteins. Analysis by SDS electrophoresis followed by 
silver staining revealed a 47 kDa protein that interacts with the LamB1 5’-UTR (Figure 5A). 
This protein was identified as La/SSB by Western blot analysis (Figure 5B). The La protein 
as well as the 37 kDa protein hnRNP A1 bound to the XIAP control RNA. Both ITAFs have 
been described as regulators of XIAP IRES activity and therefore demonstrate the selectivity 
of this experimental approach [41, 42]. The control reaction using streptavidin beads alone 
did not yield any proteins (Figure 5A and 5B). From these data we concluded that La 
selectively binds the LamB1 5’-UTR in vitro.  
This interaction was verified in vivo by anti-La RNA immunoprecipitation (IP) (Figure 5C). 
Lysates were generated from SW480 or HEK293 cells after UV crosslinking of RNA-protein 
complexes. Cell lysates were immunoprecipitated with magnetic beads conjugated to La 
antibody or unconjugated beads as control. RNA was isolated from either cell lysates (Input), 
IP with anti-La conjugated beads (La) or unconjugated beads (beads) and RT-PCR was 
performed. To exclude the presence of DNA contaminations, a control reaction without 
reverse transcription (r.t.) was included. The ability of the antibody to precipitate the La 
protein was verified by Western blot (Supplementary Figure S1). As shown in Figure 5C, 
LamB1 and XIAP but not Actin transcripts could be amplified from the immunoprecipitated 
mRNA in both cell lines. While XIAP serves as a positive control, actin mRNA is known to 
lack interaction with La, showing the selectivity of the IP [45]. Thus, these data indicate the 
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physical interaction of La with the LamB1 mRNA in two different human cell lines. To further 
investigate this interaction and analyze whether La binds the LamB1 5’-UTR in vivo, the La-
IP was performed in HEK293 cells transfected with the bicistronic construct containing either 
the LamB1 5’-UTR, the XIAP IRES or the empty control. RT-PCR for the CAT reporter 
revealed that La selectively binds the LamB1 5’-UTR and XIAP IRES but not the empty 
vector (Figure 5D). Taken together, these data show that La associates with the LamB1 5’-
UTR in vitro and in vivo. 
La binding to the LamB1 IRES is regulated upon EMT 
Since La represents an ITAF that binds to the LamB1 5’-UTR, we next investigated whether 
the interaction between La and the LamB1 IRES is regulated during EMT. Therefore we 
performed La RNA-IP employing epithelial MIM-R and fibroblastoid MIM-RT hepatocytes. 
Cells were transfected with bicistronic vectors containing the minimal LamB1 IRES, the XIAP 
IRES or the empty control. RT-PCR for the CAT reporter revealed that La binds to the 
LamB1 and XIAP IRES in MIM-R as well as MIM-RT cells (Figure 6A). qPCR for the CAT 
reporter was performed to reliably quantify the amount of LamB1 bicistronic transcripts that 
interact with La in each cell line (Figure 6B). Quantified levels of immunoprecipitated 
bicistronic transcripts were normalized to the amount of bicistronic transcript that was used 
for the IP. Interestingly, higher levels of La protein associated with the minimal LamB1 IRES 
in MIM-RT cells than in MIM-R cells suggesting that the interaction of La with the LamB1 5’-
UTR is upregulated after EMT. This observation is consistent with the bicistronic assay that 
revealed a significant increase of IRES activity upon EMT (Figure 2F) and with recent data 
showing that La is an activator of several cellular IRESs [42, 46, 47]. We further investigated 
the regulation of La during EMT in our cell model. Western blot analysis revealed 
comparable levels of La protein in MIM-R and MIM-RT cells, while LamB1 expression was 
clearly elevated in EMT-transformed cells (Figure 6C). Thus, La is not regulated during EMT 
at the level of total protein expression. As recent reports described that La can shuttle 
between nucleus and cytoplasm, we studied this possible mode of regulation by subcellular 
fractionation. Interestingly, Western blot analysis showed that MIM-RT cells display 
increased cytoplasmic La levels compared to MIM-R cells (Figure 6D). In addition, treatment 
of MIM-R cells with TGF-β resulted in slightly enhanced cytoplasmic levels of La protein. 
Notably, elevated levels of cytoplasmic La correlated with LamB1 upregulation. In summary, 
these data suggest that La protein accumulates in the cytoplasm during TGF-β induced EMT, 
where it binds to the minimal LamB1 IRES motif to increase translation. 
LamB1 IRES activity is enhanced by La 
As the interaction of La with the LamB1 IRES is regulated upon EMT, we investigated 
whether La enhances IRES-mediated translation of LamB1. Therefore, we studied the effect 
of La on LamB1 IRES activity using an in vitro translation assay (Figure 7A). Rabbit 
Dissertation                                                                                                Michaela Petz 
 82   
reticulocyte lysate (RRL) was programmed with in vitro transcribed bicistronic RNA 
containing the LamB1 5’-UTR and the IRES-dependent CAT activities were determined. Prior 
to in vitro translation, RRL was precleared from La with magnetic beads conjugated to La 
antibody or incubated with unconjugated beads as control. The preclearing of lysates was 
verified by Western blot analysis (Supplementary Figure S2). Treatment with unconjungated 
beads resulted in a slight decrease of CAT activity suggesting that some factors required for 
LamB1 IRES translation unspecifically bind to the beads. When RRL was precleared from 
La, the CAT activity was further significantly decreased (Figure 7A). Notably, the reduced 
LamB1 5’-UTR mediated translation could be restored by addition of recombinant La. These 
results suggest that La positively affects IRES-driven translation of LamB1. Since La has 
been described as activator of XIAP IRES translation, we employed the minimal XIAP IRES 
in the same experimental setting, which led to similar results (Supplementary Figure S3; 
[42]). These data suggest that La works as an ITAF that binds to the minimal LamB1 IRES 
and enhances its translational activity during hepatocellular EMT.  
To study the effect of La on LamB1 IRES translation in vivo, we generated MIM-R and MIM-
RT cells with a stable knock-down of La expression. Western blot analysis revealed a strong 
knock-down of La using two different shRNA constructs (shLa 84, shLa 87) as compared to 
non-target control (sh-NT) or untreated cells (ctrl) (Figure 7B). Notably, MIM-RT but not MIM-
R cells showed reduced levels of LamB1 after knock-down of La. These data suggest that La 
mediated stimulation of IRES-driven LamB1 translation after EMT is diminished by silencing 
of La. To further study the effect of impaired La expression on LamB1 IRES activity, 
bicistronic assays were performed (Figure 7C). MIM-R and MIM-RT cells with a stable knock-
down of La (shLa 84, shLa 87), non-target shRNA (sh-NT) or the untreated control (ctrl) were 
transfected with a bicistronic vector containing the LamB1 5’-UTR. Remarkably, LamB1 IRES 
activity was significantly reduced in EMT-transformed MIM-RT cells harboring a La knock-
down. In contrast, the knock-down of La had no significant effect on LamB1 IRES activity in 
MIM-R cells. These data concurs with the regulation of LamB1 protein expression (Figure 
7B), indicating that La enhances IRES-mediated translation during EMT, which is impaired 
after knock-down of La. 
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8.5. Discussion 
LamB1 is the β-subunit of laminin isoforms that constitute the ECM and contribute to tumor 
invasion and metastasis. The control of LamB1 expression at the transcriptional level by 
retinoic acid is well described, while the regulation at the level of translation is poorly 
understood [48]. We recently provided first evidence for IRES-mediated translation of LamB1 
5’-UTR by using bicistronic Renilla-Firefly luciferase assays [22]. However, it has been 
reported that the level of IRES activity can strongly vary depending on the type of bicistronic 
reporters [39, 40]. In addition, suspicious splicing has been detected with a Renilla-Firefly 
luciferase vector [37, 38]. To verify our recent results, we therefore utilized an alternative 
bicistronic system encoding β-gal as upstream and CAT as downstream reporter [37]. 
Consistently, the LamB1 5’-UTR was able to mediate cap-independent translation of the 
downstream cistron in murine and human cell lines (Figure 2). Interestingly, the bicistronic 
activity of LamB1 and minimal XIAP IRES was similar in human SW480 colon cancer cells 
while it was strongly increased in murine MIM hepatocytes. These data indicate that the 
LamB1 IRES activity depends on the cellular context rather than on the bicistronic vector 
used for the determination of IRES activity.  
Since bicistronic activity of the downstream reporter may result from cryptic promoter or 
splice sites within the 5’-UTR, we performed various assays to reliably exclude aberrant 
transcripts. Northern blot analysis as well as qPCR for β-gal and CAT reporters did not reveal 
any truncated bicistronic mRNAs (Figure 3). Noteworthy, the accurate determination of 
cryptic promoter activity by employing a monocistronic Firefly luciferase vector resulted in 
residual reporter activities after removal of the CMV promoter (Figure 3C). These enzymatic 
activities were detected independently of the presence or absence of LamB1 5’-UTR. RT-
PCR revealed short transcripts generated by the Firefly luciferase reporter of the 
promoterless vector indicating a cryptic activity of the reporter itself as already described 
(Figure 3D, [43]). Thus, stringent assays to detect aberrant transcripts corroborate a bona 
fide IRES activity of the LamB1 5’-UTR [22], which requires a minimal cis-acting IRES motif 
localized between -293 and -1 nts upstream of the start codon (Figure 4) 
IRES-mediated de novo synthesis of proteins involved in angiogenesis, apoptosis or mitosis 
plays an important role during tumorigenesis. We initially found by expression profiling that 
LamB1 is translationally upregulated in Ras-transformed hepatocytes (MIM-R) that undergo 
EMT in response to TGF-β (MIM-RT) [22]. In this study, the bicistronic assay showed a 2.7-
fold increase of IRES activity in EMT-transformed cells suggesting that elevated LamB1 
levels result from activated IRES translation (Figure 2E). However, diverse mechanisms are 
known to account for selective translational control in cancer cells including alternative 
splicing of the 5’-UTR or 3’-UTR shortening through alternative cleavage or polyadenylation 
[33, 36]. To test a possible involvement of transcript species in the regulation of LamB1 
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expression during tumorigenesis, we performed RACE-PCR of the 5’- and 3’-UTR. No 
alternative transcript variants could be detected in different human carcinoma cell lines 
(Figure 1B). These results are consistent with Northern blot analysis suggesting that LamB1 
translation is not regulated by alternative splicing or 3’-UTR shortening (Figure 1C). 
Therefore, the elevated translation of LamB1 upon EMT is caused by IRES activation and 
does not involve alternative splicing or 3’-UTR shortening. 
Hence, we next aimed to identify ITAFs that interact with the LamB1 IRES and activate its 
translation upon EMT. Streptavidin-tethered RNA affinity purification with a transcript 
containing the LamB1 5’-UTR downstream of two S1 aptamers revealed that La selectively 
binds the 5’-UTR in vitro (Figure 5A). This finding was verified in vivo by an anti-La RNA-IP of 
UV crosslinked cells in two human cell lines (Figure 5C). Consistent with our data, a recently 
published RNA-IP of BCR/ABL-transformed myeloid cells revealed LamB1 mRNA associated 
to La but not to hnRNP A1, hnRNP E2 or hnRNP K [45]. Furthermore, La binds the LamB1 
5’-UTR as well as the minimal LamB1 IRES within the bicistronic transcript after transient 
transfection of cells (Figure 5D, 6A). The amount of La that is associated with the minimal 
IRES is significantly elevated in EMT-transformed MIM-RT cells as compared to MIM-R 
hepatocytes (Figure 6B). Accordingly, Western blot analysis of cytoplasmic and nuclear cell 
fractions revealed the cytoplasmic translocation of La in response to TGF-β induced EMT 
(Figure 6D). Furthermore, La enhanced LamB1 IRES activity in an in vitro translation assay 
(Figure 7A), suggesting that the elevated levels of LamB1 in EMT-transformed cells results 
from increased IRES-mediated translation in the presence of cytoplasmic La. In line with 
these data, the stable knock-down of La significantly reduced LamB1 IRES activity of a 
bicistronic construct in EMT-transformed cells (Figure 7C). In addition, endogenous LamB1 
protein levels were decreased in La-silenced cell lines (Figure 7B). In contrast, La knock-
down in epithelial cells did not affect LamB1 IRES translation and endogenous LamB1 
protein levels. In summary, these results suggest that La accumulates in the cytoplasm 
during hepatocellular EMT, where it binds the minimal LamB1 IRES motif to enhance IRES-
mediated translation.  
A role of La in the LamB1 regulation during EMT is of particular interest as recent studies 
suggest an important role of La in carcinogenesis. La is a RNA binding protein involved in 
RNA processing and translation that predominantly localizes in the nucleus [49]. Elevated La 
levels have been reported in chronic myeloid leukaemia cells, cervical cancer and several 
types of cancer cell lines [22, 50, 51]. La was shown to activate IRES-dependent translation 
of XIAP which supports tumorigenesis by preventing apoptosis [42]. In addition, La regulates 
the IRES-mediated expression of cyclin D1 that stimulates cell proliferation [22]. Accordingly, 
we found cyclin D1 translationally upregulated in MIM-RT hepatocytes that have undergone 
EMT by employing polysome-bound versus total RNA (data not shown). Furthermore, AKT-
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dependent shuttling of La to the cytoplasm leads to translational activation of a specific 
mRNA subset in glial cells suggesting that La could be involved in oncogenic effects of 
aberrant AKT activation in cancer cells [52]. In this respect, it will be of relevance to dissect 
the molecular mechanisms of La activated LamB1 IRES translation in the context of EMT 
that is induced by the synergy of Ras and TGF-β signaling and involves the activation of AKT 
and MAPK pathways [21].  
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 Figures 
 
 
Figure 1. LamB1 UTRs in cancer cells. (A) The entire LamB1 5’-UTR containing 335 nts was 
amplified from various human cancer cells. Non-treated (nt), DNase- (D) or DNase plus 
RNase-treated (D/R) mRNA populations were subjected to RT-PCR (M, marker). (B) RACE-
PCR of the LamB1 5’- and 3’-UTR in human cancer cell lines resulted in single amplicons of 
expected size. (C) Northern blot analysis revealed a single LamB1 transcript.  
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Figure 2. The LamB1 5’-UTR shows IRES activity that is activated during EMT. (A) Vectors 
employed for the bicistronic assay contain the full length LamB1 5’-UTR or the minimal XIAP 
IRES within the linker region of the β-galactosidase (β-gal) and chloramphenicol transferase 
(CAT) reporter. The empty vector is taken as negative control. (B) SW480 colon carcinoma 
cells were transfected with bicistronic vector and β-gal and CAT activities were determined 
after 48 hours. β-gal and CAT activities were normalized to transcript levels as quantified by 
qPCR. (C) The LamB1 5’-UTR as well as the XIAP display IRES activity in human SW480 
cells. Shown is the ratio of IRES-mediated CAT to cap-dependent β-gal translation. (D) β-gal 
and (E) CAT activities of MIM-1-4, MIM-R and MIM-RT cells each transfected with bicistronic 
vectors. Cells were lysed after 48 hours and reporter activities were normalized to mRNA 
levels as quantified by qPCR. (F) As depicted by the ratio of CAT to β-gal activity, MIM-RT 
cells that have undergone EMT by TGF-β show significant upregulation of LamB1 IRES 
activity as compared  to Ras-transformed malignant MIM-R hepatocytes. * p<0,05, ** p<0,01 
or *** p<0,005.  
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Figure 3. LamB1 IRES activity is not affected by cryptic promoter or splice sites. (A) North-
ern blot analysis of murine MIM-R hepatocytes and human SW480 colon cancer cells trans-
fected with bicistronic constructs. Hybridization with probes for the β-gal and CAT reporter 
revealed single transcripts of equal size. Arrows indicate the position of 28S and 18S rRNA 
on the blot. 28S rRNA is shown as a loading control. (B) qPCR for β-gal and CAT in cells 
transfected with bicistronic vectors were normalized to RhoA levels, resulting in equal CAT to 
β-gal ratios for the vector containing LamB1 5’-UTR and empty control. (C) To test cryptic 
promoter activity in the LamB1 5’-UTR, the sequence was cloned upstream of a Firefly lucif-
erase reporter and the CMV promoter was removed. The viral EMCV IRES and the empty 
vector were used as negative controls. Vectors were co-transfected with a ß-gal expressing 
plasmid into MIM-R cells. Firefly luciferase activites were measured after 48 hours and nor-
malized to β-gal activities. (D) The cryptic promoter activity of the Firefly reporter was ana-
lyzed by linear semiquantitative RT-PCR using primer localized within the LamB1 5’-UTR 
(A,B,C) or the Firefly luciferase ORF (D,E,F). Arrows mark the position of forward primer 
each giving rise to an amplicon with 400-500 nts. Samples were treated with RNase to detect 
DNA contaminations. 
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Figure 4. Cis-acting sequence requirements for LamB1 IRES activity. The sequence of the 
LamB1 5’-UTR was deleted in steps of approximately 50 nts starting from the 5’-UTR or 3’-
UTR and cloned into the bicistronic β-gal/CAT reporter vector. IRES activities of bicistronic 
vectors were determined after transfection into MIM-R and MIM-RT cells. Lysates were 
analyzed after 48 hours post transfection and CAT activities were normalized to β-gal 
activities.  
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Figure 5. Identification of La interacting with the LamB1 IRES. (A) The LamB1 5’-UTR or 
XIAP minimal IRES were cloned into the pTrap vector. In vitro transcription of the linearized 
vector resulted in transcripts containing two S1 aptamers that bind streptavidin followed by 
the sequence of interest. The transcripts were linked to streptavidin beads and employed to 
pull down proteins from HEK293 cell extract. RNA-protein complexes were subjected to SDS 
electrophoresis. Silver staining shows a 47 kD protein interacting with both the LamB1 and 
XIAP IRES and a 37 kD protein interacting with the XIAP IRES only. (B) Proteins were 
identified by Western blotting as La (47 kD) and hnRNPA1 (37 kD). (C) Lysates of UV 
crosslinked SW480 and HEK293 cells were subjected to RNA-IP using the La antibody 
followed by RT-PCR for LamB1. cDNA was generated with or without reverse transcriptase 
(r.t.) to detect DNA contaminations. (D) HEK293 cells were transfected with bicistronic 
vectors, UV crosslinked after 48 hours and subjected to RNA-IP employing the La antibody 
followed by RT-PCR for CAT.  
 
 
 
Dissertation                                                                                                Michaela Petz 
 96   
 
Figure 6. The binding of La to the LamB1 IRES is regulated upon EMT. (A) MIM-R and MIM-
RT cells were transfected with bicistronic vectors containing the minimal LamB1 IRES, the 
minimal XIAP IRES or the empty control and after 48 hours UV crosslinked prior to cell lysis. 
Cell extracts were immunoprecipitated with La antibody followed by RT-PCR for the CAT 
reporter. cDNA was generated with or without reverse transcriptase (r.t.) to detect DNA 
contaminations. (B) Levels of La bound to LamB1 bicistronic transcripts were quantified by 
qPCR and normalized to LamB1 RNA input levels. (C) Total protein levels of La and LamB1 
in MIM1-4, MIM-Ras and MIM-RT cells were analyzed by Western blotting. (D) Nuclear and 
cytoplasmic fractions of MIM-R and MIM-RT cells as well as MIM-R hepatocytes treated for 
24 hours with 2,5 ng/ml TGF-β analyzed by Western blotting. The purity of cytoplasmic and 
nuclear cell fractions was assessed by tubulin and nucleoporin, respectively. 
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Figure 7. La stimulates IRES-driven LamB1 translation. (A) Rabbit reticulocyte lysate was 
programmed with the bicistronic vector containing the LamB1 5’-UTR. Lysates were 
precleared (precl.) with beads crosslinked to La antibody (+) or with nonconjugated beads 
(beads). Depletion of La from lysates reduced LamB1 IRES-mediated translation of the CAT 
reporter and addition of 1 µg recombinant La restored LamB1 IRES activity. * p<0,05. (B) 
MIM-R and MIM-RT cells were lentivirally infected with two different shRNA contructs against 
La (shLa 84, shLa 87) or non-target shRNA (sh-NT). The knock-down of La compared to the 
untreated control (ctrl) as detected by Western blotting. (C) The generated cell lines were 
transfected with a bicistronic vector containing the LamB1 5’-UTR. Lysates were analyzed 48 
hours post transfection and CAT activities were normalized to β-gal activities. * p<0,05 or ** 
p<0,01. 
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8.9. Supplementary Data 
 
Supplementary Table S1. Primer containing NheI and XhoI restriction sites. Used to amplify 
fragments of the LamB1 5’-UTR, which were cloned into the bicistronic vector pβgal/CAT for 
mapping of the minimal IRES motif. 
description forward reverse 
pβgal(42-335)CAT gctagcggctttcaaacaaaagag gcgctcgaggccggctccct 
pβgal(94-335)CAT gctagctcctcgcagagttg gcgctcgaggccggctccct 
pβgal(155-335)CAT cctagctagcaggcgcctccct gcgctcgaggccggctccct 
pβgal(200-335)CAT cctagctagcttctttgggctcggg gcgctcgaggccggctccct 
pβgal(253-335)CAT cctagctagcggaagacgggaag gcgctcgaggccggctccct 
pβgal(1-42)CAT gctagcgggacctggaagcgccccag ctcgagcgaatctgcgatcgctgcg 
pβgal(1-94)CAT gctagcgggacctggaagcgccccag ctcgagaccgggtgaggtcccg 
pβgal(1-155)CAT gctagcgggacctggaagcgccccag ctcgagtctgctcatgcgcatacgg 
pβgal(1-200)CAT gctagcgggacctggaagcgccccag ctcgagagggaattagaaagtttagccttggg 
pβgal(1-253)CAT gctagcgggacctggaagcgccccag ctcgagctttccggcgacgcgagct 
pβgal(42-253)CAT gctagcggctttcaaacaaaagag ctcgagctttccggcgacgcgagct 
Supplementary Table S2. Primer containing KpnI and BamHI restriction sites. Used for am-
plification of the LamB1 5’-UTR or minimal XIAP IRES sequence, which were cloned into the 
pTrap vector. 
description forward reverse 
LamB1 5’-UTR gcgcggtaccgggacctggaagcgccccag gcgcggatccgccggctccctgcagccacg 
XIAP IRES gcgcggtaccctcgagattagaatgtttc gcgcggatccgcttctcttgaaaaragga 
Supplementary Table S3. Primer used for RT-PCR. 
description forward reverse 
human LamB1 ggcgtcttctccactcctct gcatagcagctggacggaat 
human XIAP cttgtgtacctgcagacatc agagtccagcacttgctaac 
RhoA ggaagaaactggtgattgttggtg tcgtggttggcttctaaatactgg 
Actin agcacggcatcgtcaccaac ggcgacgtagcacagcttct 
CAT reporter accagaccgttcagctggat ccttgtcgccttgcgtataa 
Supplementary Table S4. Primer for SYBR green quantitative RT-PCR. 
description forward reverse 
β-gal reporter actatcccgaccgccttact ctgtagcgctgatgttgaa 
CAT reporter gcgtgttacggtgaaaacct gggcgaagaacttgtccata 
RhoA ggaagaaactggtgattgttggtg tcgtggttggcttctaaatactgg 
murine LamB1 caggaaccggagttcagcta gcaggtggctaacaatacag 
Supplementary Table S5.  Primer used for the RACE-PCR of the human LamB1 5’-UTR 
and 3’-UTR . 
description forward reverse 
3’ outer primer ctgacattgccagagctgagat  
3’ inner primer ggatccagataaagctcaagaattagcaagac  
5’ outer primer  tgcaagtggctgacgatacagtag 
5’ inner primer  ggatcccgggctctgcacagggctaagaaa 
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Supplementary Table S6. Primer used to generate Northern blot probes specific for tran-
scripts of the bicistronic vector containing the LamB1 5’-UTR (pβgal/Lam/CAT). 
description forward reverse 
β-gal probe aagcagaagcctgcgatgtc gccgtggcctgattcattcc 
CAT probe accagaccgttcagctggat ccttgtcgccttgcgtataa 
 5’UTR probe ccccgcagcgatcgcagatt gcggcagaggagtggagaag 
Supplementary Table S7. Primer used to detect cryptic Firefly luciferase activity of the 
pLam-F vector, which contains the LamB1 5’-UTR upstream of the Firefly luciferase reporter. 
description forward reverse 
A gggacctggaagcgccccag ggcgtcttccatggtggctt 
B tctgttcctcccaaggctaa ccgaacggacatttcgaagt 
C ggagccggcctcgagatctg acaccacggtaggctgcgaa 
D ctcccggttttaatgaatac tgtcaatcagagtgcttttg 
E ttgaagaagagctgtttctg gcttccggattgtttacata 
F gcgcggtcggtaaagttgtt gcgacgtaatccacgatctc 
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Supplementary Figure S1. Western blot analysis of La-RNA immunoprecipitation. RNA-
protein complexes of UV crosslinked HEK293 or SW480 cells were immunoprecipitated with 
La antibody. Aliquots of cell lysates (input) and immunoprecipitations performed with anti-La 
conjungated (La-IP) or unconjugated (control) beads were treated with RNase A and sub-
jected to Western blot analysis.  
 
Supplementary Figure S2. Levels of La protein in rabbit reticulocyte lysates used for in 
vitro translation assays of LamB1 and XIAP. The preclearing of La in rabbit reticulocyte 
lysates was analyzed by Western blotting. La levels were determined in lysates precleared 
(precl.) with unlinked beads (b) or beads crosslinked to La antibody (+) and after addition of 1 
µg recombinant La (lower panel). SDS-buffer eluates of beads used for preclearing show La 
that was immunoprecipitated from the lysates (upper panel). 
  
Supplementary Figure S3. XIAP IRES activity depends on La. Rabbit reticulocyte lysate 
was programmed with the bicistronic vector containing the minimal XIAP IRES. Lysates were 
precleared (precl.) with unlinked beads (beads) or beads crosslinked to La antibody (+). 
Removal of La from lysates reduced XIAP IRES-mediated translation of the CAT reporter, 
whereas addition of 1 µg recombinant La restored IRES activity. 
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9.1. Abstract 
The extracellular matrix protein Laminin B1 (LamB1) regulates tumor cell migration and 
invasion. Carcinoma cells acquire invasive properties by epithelial to mesenchymal transition 
(EMT) which is a fundamental step in dissemination of metastatic cells from the primary 
tumor. Recently, we showed that enhanced translation of LamB1 upon EMT of malignant 
hepatocytes is mediated by an internal ribosome entry site (IRES). We demonstrated that the 
IRES transacting factor La binds the minimal IRES motif and positively modulates IRES 
activity of LamB1. Here we show that platelet-derived growth factor (PDGF) enhances IRES 
activity of LamB1 by the increasing cytoplasmic localization of La during EMT. Accordingly, 
cells expressing dominant negative PDGF receptor display reduced cytoplasmic 
accumulation of La and show no elevation of IRES activity or endogenous LamB1 levels after 
stimulation with PDGF. Furthermore, La mediated regulation of LamB1 IRES activity 
predominantly depends on MAPK/ERK signaling downstream of PDGF. Notably, LamB1 
expression is not significantly downregulated by the impairment of the translation initiation 
factor eIF4E. In vivo, knock-down of La associated with decreased LamB1 expression and 
reduced tumor growth. Together, these data suggest that PDGF is required for the 
cytoplasmic accumulation of La that triggers IRES-dependent translation of LamB1 during 
EMT. 
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9.2. Introduction 
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide with 
increasing incidence over recent years [1 , 2]. The majority of HCC develops as a 
consequence of chronic liver inflammation and is preceded by liver fibrosis and cirrhosis [3]. 
Main reasons for the high mortality rate of patients with HCC are the late diagnosis at an 
advanced stage of disease and intrahepatic metastasis [4]. HCC derives from the neoplasia 
of hepatocytes which are highly differentiated and metabolically specialized epithelial cells 
[5]. During HCC progression, trans-differentiation of hepatocytes frequently occurs through 
epithelial to mesenchymal transition (EMT), which is characterized by abrogation of cell-cell 
contacts and acquisition of a fibroblastoid, highly motile phenotype [6]. EMT-transformed 
malignant hepatocytes show metastatic abilities by disseminating from the primary tumor and 
invading the surrounding tissue [7]. Dissociation of adherence junctions is accompanied by 
loss of cell polarity and cytoskeletal rearrangements [8]. It involves changes in integrin 
expression and distribution [9]. Integrins are a family of heterodimeric transmembrane 
receptors that connect the extracellular matrix (ECM) to the cytoskeleton of the cell. In 
particular, integrin β1 complexes are upregulated in Ras-transformed cells that have 
undergone EMT in response to transforming growth factor (TGF)-β [9-11]. They potentiate 
growth factor receptor driven MAPK/ERK and PI3K/AKT signaling and activate latent TGF-β 
[12, 13]. Moreover, β1 integrin mediated MAPK/p38 activation was found to be essential for 
EMT [14]. The extracellular interaction partners of integrins are laminins which are the main 
non-collagenous component of the ECM [15]. Laminins are heterotrimeric glycoproteins 
composed of several different α, β, and γ subunits which assemble in fifteen laminin isoforms 
that are expressed in a tissue specific manner [16]. Laminin B1 (LamB1) is the β1 subunit of 
six laminin isoforms including laminin 1 that is expressed in hepatocytes [16, 17]. LamB1 
mediates β1 integrin signaling and activates a specific p67kDa laminin receptor (LamR) that 
regulates cell migration, proliferation and survival [18, 19]. Proteome profiling of HCC 
patients showed elevated LamB1 levels in cirrhotic liver tissues and a further increased 
expression in HCC cells [20]. Concomitantly, β1 integrin receptors and LamR were found to 
be upregulated in HCC correlating with increased tumor aggressiveness as well as poor 
patient survival [21, 22]. EMT-transformed cells rearrange their extracellular surrounding by 
enhanced secretion of ECM components as well as by cleavage through matrix 
metalloproteinases [23, 24]. This ECM remodeling facilitates tumor cell migration and 
invasion, thus essentially contributing to metastasis [24]. 
 To study EMT of HCC cells, we previously established p19ARF deficient immortalized 
hepatocytes that become tumorigenic upon expression of oncogenic H-Ras and further 
undergo EMT in response to TGF-β treatment [25]. EMT-transformed hepatocytes establish 
an autocrine TGF-β signaling loop that upregulates PDGF signaling components including 
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PDGF receptor α (PDGF-Rα) [26]. LamB1 is translationally upregulated in hepatocytes that 
have undergone EMT [27] through an internal ribosome entry site (IRES) located in the 5’-
untranslated region (UTR) of LamB1 mRNA. IRES-mediated translation of LamB1 is 
enhanced upon EMT by the cytoplasmic accumulation of the IRES transacting factor (ITAF) 
La that binds the minimal IRES motif [28]. In this study we show that the cytoplasmic 
accumulation of La is regulated by PDGF and downstream MAPK/ERK signaling in EMT-
transformed cells. Cytoplasmic levels of La are essentially required for the enhanced IRES 
translation of LamB1 in mesenchymal hepatocytes. In vivo, stable knock-down of La results 
in reduced LamB1 expression and impaired tumor formation. 
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9.3. Material and Methods 
Construction of plasmids 
The bicistronic plasmid containing the 5’-UTR of Laminin B1 (LamB1) between β-
galactosidase (β-gal) and chloramphenicol acetyltransferase (CAT) reporters was 
constructed as described recently [28]. Primers were designed according to GenBank 
sequence NM_002291. The monocistronic vector contains the LamB1 5’-UTR upstream of a 
Firefly luciferase reporter as described recently [27]. Vectors expressing 2A protease of 
rhinovirus serotype 2 (2Awt) or the inactive mutant C106A (2Amut) were generated as 
outlined [27]. 
Cell culture 
Immortalized p19ARF deficient MIM-1-4 hepatocytes were grown on collagen-coated culture 
dishes in RPMI 1640 plus 10% fetal calf serum (FCS), 40 ng/ml human TGF-α (Sigma, St. 
Louis, USA), 30 ng/ml human insulin-like growth factor II (IGF-II, Sigma, St. Louis, USA), 1.4 
nM insulin (Sigma, St. Louis, USA) and antibiotics, as described previously [29]. Epithelial 
MIM-R, MIM-S35 or MIM-C40 hepatocytes were derived from MIM-1-4 cells by stable 
retroviral transmission with a bicistronic construct expressing either oncogenic v-Ha-Ras and 
green fluorescent protein (GFP) or the Ras mutants S35-V12-Ras or C40-V12-Ras, 
respectively [25]. For interference with PDGF signaling, MIM-R cells were retrovirally 
transmitted with a bicistronic vector expressing the dominant negative (dn)PDGF receptor α 
and red fluorescent protein (RFP), resulting in MIM-RdnP [26, 30]. Treatment of the epithelial 
cell lines MIM-R, MIM-S35, MIM-C40 and MIM-RdnP with TGF-β1 (R&D Systems, 
Minneapolis, USA) for more than two weeks resulted in cells with a stable mesenchymal 
phenotype, namely MIM-RT, MIM-ST, MIM-CT and MIM-RTdnP, respectively. TGF-β1 was 
used at a concentration of 2.5 ng/ml for the first 72 hours of EMT induction. For long-term 
treatment of epithelial hepatocytes, 1 ng/ml TGF-β1 was supplemented to the medium [25]. 
Recombinant human PDGF-A/B (PeproTech, Rocky Hill, USA) was used at a concentration 
of 10 ng/ml. The pharmacological inhibitors LY294002 (Cell Signaling, MA, USA) against 
PI3K and UO126 (Cell Signaling, MA, USA) against MEK1/2 were used at a concentration of 
10 µM. The inhibitor against TGF-β-RI/II (Lilly, Indianapolis, USA) was used at a 
concentration of 20 µM. All cells were kept at 37°C and 5% CO2 and routinely screened for 
the absence of mycoplasma. 
RNA interference 
MISSION® shRNA lentiviral transduction particles (Sigma, St. Louis, USA) were used to 
stably knock-down La (NM_009278) in MIM-R and MIM-RT cells as outlined recently [28]. 
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Western blot analysis 
The preparation of cellular extracts, separation of proteins by SDS-PAGE and 
immunoblotting were performed as described [28]. Cytoplasmic and nuclear cell fractions 
were generated using a Proteo-JET® kit (Fermentas, St.Leon-Rot, Germany) according to 
the manufacturer’s description. 30 µg protein extract was loaded onto gels and 
immunological detection of proteins was performed with the Super Signal detection system 
(Pierce Chemical Company, Rockford, USA). The following primary antibodies were used: 
anti-laminin B1 (Neo Markers, Fremont, USA), 1:1000; anti-actin (Sigma, St. Louis, USA), 
1:2000; anti-La (Cell Signaling, MA, USA), 1:1000; anti-tubulin (Sigma, St. Louis, USA), 
1:1000; anti-nucleoporin (BD Biosciences, NJ, USA), 1:1000; anti-phospho-ERK (Cell 
Signaling, MA, USA), 1:1000; anti-ERK (Cell Signaling, MA, USA), 1:1000; anti-phospho-
AKT (Cell Signaling, MA, USA), 1:1000; anti-AKT (BD Biosciences, NJ, USA), 1:1000; anti-
phospho-eIF2 (Cell Signaling, MA, USA), 1:1000; anti-eIF2 (Cell Signaling, MA, USA), 
1:1000; anti-phospho-p38 (Cell Signaling, MA, USA), 1:1000; anti-p38 (Santa Cruz 
Biotechnology, California, USA), 1:1000; anti-PDGF-receptor α (Cell Signaling, MA, USA), 
1:1000. Secondary antibodies (Calbiochem, LaJolla, USA) were used at dilutions of 1:10 
000. Signals were scanned and quantified with ImageQuant 5.0 (Amersham Biosciences, 
Little Chalfont, UK). 
Quantitative polymerase chain reaction (qPCR) 
RNA was extracted, DNaseI treated and reverse transcribed using a RNA isolation and 
cDNA synthesis kit (Quiagen, Hilden, Germany) as recommended by the manufacturer. 
Aliquots of cDNA were employed for Fast SYBR green qPCR (Applied Biosystems, CA, 
USA) and quantified with the 7500 Fast Real Time PCR System (Applied Biosystems, CA, 
USA). Primer sequences are shown in Supplementary Table S1. 
Transient transfection and reporter assays 
Cells were seeded on 6-well plates and transfected after 24 hours with Lipofectamine Plus as 
recommended by the manufacturer (Invitrogen, Carlsbad, USA). Cells were lysed 48 hours 
post transfection and reporter activities were determined. Luciferase activity was measured 
with a Luminoskan microplate reader (Labsystems, Farnborough, UK) as described recently 
[27]. β-gal activity was photometrically determined using o-nitrophenyl-β-d-galactopyranoside 
and CAT activity was measured by ELISA (Roche, Mannheim, Germany) as recommended 
by the manufacturer. In assays analyzing the interference of cap-dependent translation, 
reporter activities were normalized to mRNA levels as quantified by qPCR. Otherwise, 
relative IRES activity of the bicistronic assay was calculated as the ratio of CAT/β-gal. 
Assays were performed in triplicate and results represent the average of three independent 
experiments. 
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Subcutaneous tumor formation 
Cells were detached from tissue culture plates and washed with PBS. 1x106 cells in 100 µl 
Ringer solution were each subcutaneously injected into immunodeficient C.B-17 SCID mice. 
Each cell line was injected four times. Experiments were performed according to the Austrian 
guidelines for animal care and protection. 
Immunohistochemistry 
Mice were sacrificed and tumors were fixed in paraformaldehyde as previously described 
[30]. Paraffin embedded tumor sections of 4 µm were stained with hematoxylin and eosin 
(H&E). Primary antibodies against LamB1 (Neo Markers, Fremont, USA) and La (Cell 
Signaling, MA, USA) were used at a dilution of 1:100. Biotinylated secondary antibodies were 
diluted 1:200. The immunoperoxidase procedure was performed using a Vectastain Elite 
ABC kit (Vector Laboratories Inc., CA, USA) as described by the manufacturer. DAB-Ni 
substrate (Vector Laboratories Inc., CA, USA) was employed for color development. Sections 
were counterstained with hematoxylin and mounted in Entellan®. 
Immunocytochemistry 
Cells were grown on collagen coated Superfrost® plus glass slides (Thermo Scientific, MA, 
USA) and fixed with paraformaldehyde. Primary antibodies against LamB1 (Neo Markers, 
Fremont, USA) and La (Cell Signaling, MA, USA) were used at a dilution of 1:100. 
Immunological stainings were performed as described for immunohistochemistry. 
Statistical analysis 
Data were expressed as means ± standard deviation. The statistical significance of 
differences was evaluated using a paired, non-parametric Student’s t-test. Significant 
differences between experimental groups were *P<0.05, **P<0.01 or ***P<0.005. 
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9.4. Results 
IRES mediated translation of LamB1 during EMT is enhanced by cytoplasmic La  
We employed a cellular HCC model based on p19ARF-/- hepatocytes transformed with 
oncogenic H-Ras (MIM-R) which synchronously undergo epithelial to mesenchymal transition 
(EMT) in response to TGF-β treatment (MIM-RT; [25]). Upon EMT, LamB1 was found to be 
translationally upregulated by an IRES element in the LamB1 5’-UTR [27, 28]. La was 
identified as an ITAF that interacts with the LamB1 IRES [28]. Increased levels of La were 
bound to the minimal IRES motif in EMT-transformed cells suggesting a role of La in the 
regulation of LamB1 IRES translation during EMT. In this study, we verified the increase of 
LamB1 expression in mesenchymal cells by Western blot analysis. Quantification of LamB1 
protein levels revealed a 2,5 fold upregulation during EMT (Figure 1A). In contrast, qPCR 
displayed similar LamB1 mRNA levels in epithelial MIM-R and mesenchymal MIM-RT cells 
(Figure 1B). Protein levels further showed that shRNA mediated knock-down of La 
significantly reduced LamB1 expression in mesenchymal MIM-RT cells but not in epithelial 
MIM-R cells indicating that La enhances LamB1 IRES activity after EMT (Figure 1A; [28]).  
 La is a nuclear protein that has been described to shuttle to the cytoplasm during 
apoptosis or cellular stress, where it activates IRES translation of target mRNAs [31-35]. We 
investigated the cytoplasmic localization of La during EMT by Western blot analysis of 
subcellular fractions (Figure 1C). Cytoplasmic fractions showed accumulation of La in EMT-
transformed cells whereas total La levels were not changed (Figure 1A and C). Interestingly, 
we found increased cytoplasmic La not only after EMT but also in epithelial cells after TGF-β 
treatment for 24 hours (Figure 1C). Since EMT is associated with ER-stress [36] and La 
translocates to the cytoplasm upon induction of cellular stress [34], we asked whether the 
regulatory mechanism responsible for La translocation is connected to TGF-β induced 
cellular stress. Therefore, epithelial MIM-R cells were stimulated with TGF-β and IRES 
mediated LamB1 expression was analyzed after expression of a bicistronic β-gal/CAT 
reporter during EMT kinetics (Figure 1D). β-gal activity of the first reporter shows cap-
dependent translation whereas CAT activity indicates the translation of the second reporter 
that is regulated by the LamB1 IRES. Reporter activities were normalized to mRNA levels of 
the bicistronic transcript allowing an independent estimation of cap- and IRES-dependent 
translation. Interestingly, β-gal levels decreased during the first 48 hours of TGF-β treatment, 
indicating downregulation of cap-dependent translation. Reduced cap-dependent translation 
correlated with decreased expression of the translation initiation factor (eIF)4E and increased 
eIF2α phosphorylation, suggesting cellular stress (Supplementary Figure S1). In contrast, 
cap-dependent β-gal expression was even slightly elevated at later time points of TGF-β 
treatment as well as in EMT transformed cells (RT; Figure 1D), correlating with increased 
phosphorylation of 4E-binding protein (4E-BP; Supplementary Figure S1). These data 
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indicate that epithelial cells respond to TGF-β treatment with a transient downregulation of 
cap-dependent translation that does not persist after EMT transformation. Cellular stress and 
decreased availability of eIFs or cytoplasmic accumulation of La might therefore contribute to 
the increase of LamB1 IRES translation in response to TGF-β (Figure 1C). However, EMT-
transformed cells are devoid of cellular stress and other mechanisms must be responsible for 
the enhanced LamB1 IRES translation.  
 Recently, PDGF was reported to modulate phosphorylation and subcellular 
localization of La in glioma [37]. Furthermore, PDGF signaling was found to be activated 
upon EMT and involved in cellular stress. TGF-β induced EMT of malignant hepatocytes 
shows upregulation of PDGF signaling components including PDGF-Rα (Supplementary 
Figure S1A and S1C; [26]). Kinetics of epithelial cells showed immediate activation of PDGF-
Rα expression after TGF-β treatment and in EMT-transformed cells (Figure E). Expression of 
PDGF-Rα correlated with LamB1 protein levels (Figure 1E) and IRES activity (Figure 1D), 
pointing to an involvement of PDGF signaling in the regulation of LamB1 IRES translation. 
Investigation of pathways downstream of PDGF that are activated during EMT revealed that 
MAPK/ERK rather than PI3K/AKT signaling (Figure 1F) correlated with the regulation of 
LamB1 expression (Figure 1 E). 
 In summary these data show that LamB1 IRES translation is enhanced by La which 
accumulates in the cytoplasm of EMT-transformed cells. Stimulation of epithelial cells with 
TGF-β leads to a transient downregulation of cap-dependent translation and cytoplasmic 
localization of La. PDGF-Rα expression is induced by TGF-β during EMT and correlates with 
LamB1 expression and IRES activity, suggesting a role in the regulation of LamB1 
translation.  
The cytoplasmic accumulation of La in EMT-transformed cells is regulated by PDGF 
La was reported to translocate from the nucleus to the cytoplasm where it functions as an 
ITAF by enhancing IRES translation of target mRNAs [32, 38, 39]. Multiple phosphorylation 
sites or cleavage of the C-terminal nuclear localization signal have been described to 
regulate the subcellular localization of La [35, 40, 41]. Yet, less is known about the regulation 
of La distribution, apart from a recent report showing that PDGF signaling triggers La 
phosphorylation and cytoplasmic accumulation in glioma cells [37]. To examine whether 
PDGF signaling is responsible for cytoplasmic accumulation of La and enhancement of 
LamB1 IRES translation, we used hepatocytes expressing a dominant negative version of 
PDGF-Rα (dnP) [30]. During PDGF stimulation, cells were simultaneously treated with TGF-β 
inhibitor to interfere with TGF-β driven endogenous PDGF signaling and to exclude the 
involvement of other TGF-β activated pathways. Western blot analysis of subcellular 
fractions revealed that cytoplasmic accumulation of La and enhanced LamB1 expression is 
induced by PDGF in mesenchymal MIM-RT but not in epithelial MIM-R cells (Figure 2A). 
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Expression of dnP impaired the upregulation of cytoplasmic La and LamB1. 
Immunocytochemical stainings confirmed the impact of PDGF signaling on the cytoplasmic 
localization of La (Figure 2B).  
 To investigate whether the cytoplasmic localization of La affects IRES mediated 
translation of LamB1, we assessed IRES activity with the bicistronic reporter assay. MIM-
RTdnP showed decreased LamB1 IRES activity compared to MIM-RT, indicating a role of 
PDGF in LamB1 IRES regulation (Figure 2C). Impairment of TGF-β and downstream PDGF 
signaling by treatment with TGF-β inhibitor resulted in decreased LamB1 IRES activity in 
mesenchymal MIM-RT cells but not after dnP expression (RTdnP; Figure 2C). In contrast, 
LamB1 IRES activity was not reduced in MIM-RT cells upon the simultaneous treatment with 
TGF-β inhibitor and PDGF stimulation. These data indicate that PDGF is downstream of 
TGF-β signaling and that LamB1 IRES translation in EMT-transformed cells depends on 
PDGF signaling. Noteworthy, epithelial MIM-R cells express only low levels of PDGF-Rα. 
Thus, treatment with PDGF had no effect on LamB1 IRES translation (R, RdnP; (Figure 2C), 
whereas stimulation with TGF-β induced PDGF-Rα expression and LamB1 IRES activity in 
MIM-R cells. As expected, expression of dnP impairs the TGF-β mediated induction of 
LamB1 IRES translation (RdnP). Together, these data indicate that induction of EMT by 
TGF-β activates PDGF signaling which triggers cytoplasmic accumulation of La to enhance 
LamB1 IRES translation. 
PDGF signals via PI3K and MAPK pathways 
To characterize the pathways that are involved in the PDGF mediated regulation of La, 
Western blot analysis of epithelial MIM-R, mesenchymal MIM-RT cells and those expressing 
dnP (RdnP, RTdnP) was performed (Figure 3). Treatment with TGF-β resulted in the 
activation of PI3K/AKT as well as MAPK/ERK signaling and LamB1 expression in epithelial 
and EMT-transformed cells. Expression of dnP significantly reduced activation of these 
pathways and impaired the enhancement of LamB1 expression, suggesting that PDGF 
contributes to TGF-β-induced PI3K and MAPK signaling and regulates LamB1 expression. In 
order to estimate the effect of PDGF stimulation, the TGF-β triggered endogenous PDGF 
expression was pharmacologically inhibited. In contrast to TGF-β, PDGF was exclusively 
able to induce AKT and ERK signaling in mesenchymal MIM-RT but not in epithelial MIM-R 
hepatocytes which express low levels of PDGF-Rα. Interference with PDGF signaling by dnP 
expression impaired PDGF induced AKT as well as MAPK signaling and enhancement of 
LamB1 expression. In contrast, the expression of La was not changed (Figure 3). 
Interestingly, expression of dnP strongly impaired AKT and ERK signaling in response to 
PDGF. Thus, the correlation of both ERK and AKT phosphorylation with LamB1 expression 
point to their involvement in PDGF mediated regulation of LamB1 IRES translation during 
EMT.  
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LamB1 IRES translation is predominantly regulated by MAPK signaling 
To analyze PDGF downstream signaling for the regulation of LamB1 IRES translation, we 
used cell lines expressing mutated Ras versions. C40-V12-Ras predominantly activates 
PI3K/AKT while S35-V12-Ras induces the MAPK/ERK signaling [25]. Cells that activate the 
MAPK/ERK pathway undergo TGF-β induced EMT resulting in MIM-ST cells, whereas those 
activating PI3K/AKT signaling acquire a scattering phenotype in response to TGF-β and fail 
to undergo complete EMT (MIM-CT; [25]). Cells were treated with TGF-β inhibitor and PDGF 
to trigger PDGF but not TGF-β induced signaling. As expected, PDGF treatment stimulated 
PI3K/AKT and MAPK/ERK signaling (Figure 4A). Activation of AKT was stronger in MIM-CT 
and MIM-RT while activation of ERK was higher in MIM-ST and MIM-RT cells. All cell lines 
expressed comparable levels of total La, thus being not regulated in response to PDGF 
treatment. LamB1 expression was increased in PDGF-stimulated MIM-ST but not in MIM-CT 
cells, suggesting the involvement of MAPK/ERK signaling in the regulation of LamB1 
expression. Accordingly, PDGF treatment significantly elevated LamB1 IRES translation in 
MIM-ST and MIM-RT cell lines but showed less effect in MIM-CT cells (Figure 4B). In 
agreement with these data, cytoplasmic localization of La was induced by PDGF treatment in 
MIM-ST and MIM-RT but not in MIM-CT cells (Figure 4C and Supplementary Figure S2). 
These data suggest that the PDGF-induced IRES mediated translation of LamB1 is 
predominantly regulated by MAPK/ERK signaling, which triggers the cytoplasmic 
accumulation of La. 
PI3K affects MAPK-dependent regulation of cytoplasmic La localization 
To further examine the PDGF signaling on LamB1 IRES translation, we selectively inhibited 
PI3K/AKT or MAPK/ERK signaling in EMT-transformed MIM-RT cells using small molecule 
inhibitors targeting PI3K or MEK1/2. Inhibition of the PI3K/AKT signaling did neither affect 
LamB1 expression nor cytoplasmic levels of La (Figure 5A). In contrast, MEK1/2 inhibition 
resulted in a significant reduction of LamB1 and cytoplasmic La levels, which was even more 
lowered by combined inhibitor treatment. In accordance, inhibition of MEK1/2 reduced 
LamB1 IRES activity which was even more inhibited through the combined treatment while 
interference with PI3K/AKT alone had no significant effect (Figure 5B). These results suggest 
that cytoplasmic accumulation of La and the enhanced IRES driven expression of LamB1 is 
mainly regulated by MAPK/ERK signaling with an additional impact of the PI3K/AKT 
pathway.  
 Inhibition of the MAPK/ERK pathway leads to reduced eIF4E activity [42] which could 
be involved in the downregulation of cap-dependent LamB1 expression. To estimate whether 
decreased eIF4E availability could influence the expression of LamB1, a reporter assay was 
performed in the presence of 2A protease. This enzyme cleaves the eIF4E binding site on 
eIF4G and therefore disrupts the association of eIF4E with the translation preinitiation 
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complex [43]. We expressed 2A protease (2Awt) or the inactive mutant (2Amut) together with 
a reporter plasmid containing the LamB1 5’-UTR in front of a Firefly luciferase reporter. 
Firefly luciferase activity therefore reflects both the cap-dependent and IRES mediated 
translation of LamB1. To detect the impairment of cap-dependent translation by 2A protease, 
2Awt or 2Amut was co-transfected with the empty reporter vector expressing Firefly 
luciferase. Interestingly, cap-dependent translation was significantly reduced by 2A protease 
activity while translation of the LamB1 5’-UTR containing reporter was not impaired (Figure 
5C). Similar experiments were performed recently with a bicistronic vector showing that 2A 
protease activity leads to increased IRES translation of LamB1 [27]. Together, these results 
suggest that reduced eIF4E availability leads to enhanced IRES mediated translation of 
LamB1 which compensates a possible reduction of cap-dependent translation and stabilizes 
protein expression of LamB1. Notably, the decrease of eIF4E activity has been reported to 
reduce cap-dependent and to induce IRES mediated translation [44]. Diminished LamB1 
expression upon inhibition of MAPK/ERK signaling can therefore not be explained by the 
reduction of cap-dependent translation. Thus, inhibition of MAPK/ERK does not induce a 
possible switch to IRES translation of LamB1. Rather, MAPK/ERK pathway regulates IRES 
mediated translation of LamB1 by the modulation of La translocation. 
PDGF regulated subcellular localization of La correlates with LamB1 levels in vivo  
We next addressed the question whether the localization of La correlates with LamB1 
expression and the tumor formation of EMT-transformed cells in vivo. Therefore, epithelial 
MIM-R or mesenchymal MIM-RT cells as well as those expressing dnP or a stable 
knockdown of La (shLa84, shLa87) or the non-target control (shNT) were xenografted for 
subcutaneous tumor formation. Interestingly, the knock-down of La as well as the 
intervention with PDGF signaling significantly reduced subcutaneous tumor growth of EMT-
transformed cells (Figure 6A and Supplementary Figure S3). Expression of LamB1 was 
analyzed in cell lysates or subcellular fractions obtained from tumor tissues. The knock-down 
of La in EMT-transformed cells decreased LamB1 expression, showing that enhanced 
LamB1 expression depends on La even under in vivo conditions (Figure 6B). Analysis of 
subcellular fractions from mesenchymal MIM-RT-derived tumors revealed a cytoplasmic 
accumulation of La and increased LamB1 expression in vivo (Figure 6C). Furthermore, 
intervention with PDGF signaling decreased the cytoplasmic accumulation of La as well as 
LamB1 expression. No changes in La localization could be observed in cell lysates from 
tumors generated by epithelial cells (data not shown). Immunohistochemical analysis further 
confirmed the link between cytoplasmic La and increased LamB1 levels in tumors derived 
from EMT-transformed cells. Tumors generated from MIM-RT cells expressing dnP showed a 
lack of cytoplasmic La which correlated with lowered LamB1 expression upon EMT as 
compared to control or shNT (Figure 6D). Similarly, reduced levels of LamB1 were observed 
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in tumors with a knock-down of La. In summary, these data provide strong evidence that 
endogenous, tumor-derived TGF-β levels are sufficient to induce PDGF mediated 
accumulation of La and to enhance LamB1 expression upon hepatocellular EMT.  
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9.5. Discussion 
EMT is a crucial step in the metastatic cascade that provides carcinoma cells with the ability 
to remodel and cross the ECM of the basement membrane as well as to enter circulation [7]. 
Hepatocellular EMT is induced by the cooperation of oncogenic Ras and TGF-β signaling 
and essentially depends on the activation of PDGF signaling [26]. Here we present evidence 
that PDGF triggers the cytoplasmic accumulation of La during EMT in a PDGF-Rα dependent 
way. Cytoplasmic La acts as an ITAF and enhances IRES mediated translation of LamB1 in 
cells that have undergone EMT [28]. To our knowledge these are the first data describing the 
cytoplasmic shuttling of La during EMT and its regulation by PDGF-Rα that controls IRES 
activity. 
 Autocrine secretion of TGF-β results in a persistent PDGF expression in EMT 
transformed hepatocytes. Interference with TGF-β and PDGF signaling with small molecule 
inhibitors or expression of a dnP revealed that cytoplasmic accumulation of La and IRES 
driven translation of LamB1 depends on active TGF-β signaling and downstream PDGF-Rα 
expression. Furthermore, we found that PDGF contributes to the activation of MAPK/ERK 
and PI3K/AKT pathways in mesenchymal cells. Experiments with hepatocytes expressing 
mutated Ras versions clearly indicate that La translocation and LamB1 IRES translation 
during EMT is regulated by MAPK/ERK signaling. Yet, combined pharmacological inhibition 
of MAPK/ERK and PI3K/AKT pathways had a more significant effect than sole inhibition of 
MEK1/2, suggesting that active PI3K/AKT signaling contributes to La translocation. 
Accordingly, kinetics of TGF-β induced EMT show a more prominent upregulation of LamB1 
IRES activity at later time points correlating with elevated PI3K/AKT signaling (Figure 1D and 
F). Importantly, an assay employing 2A protease expression showed that the effects 
observed upon MEK1/2 or AKT inhibition are not merely a result of decreased eIF4E 
availability, but rather depend on cytoplasmic accumulation of La. 
 PDGF signaling was not only activated in EMT transformed cells, but also shortly 
after TGF-β stimulation of epithelial cells (Figure 1E). Cap-dependent translation is reduced 
during 48 hours post TGF-β treatment. This reduction correlates with increased eIF2α 
phosphorylation and activation of the p38/MAPK pathway, pointing to cellular stress (Figure 
1F, Supplementary Figure 1D). Indeed, a link between EMT and ER-stress has been 
reported in thyroid cells [36]. Activation of PDGF-Rα expression as well as cytoplasmic 
localization of La in response to cellular stress has been described recently [33, 34]. PDGF-
Rα was found to signal via Src during cellular stress. However, experiments with 
pharmacological inhibitors against Src or Janus kinases had no effect on LamB1 IRES 
activity (data not shown). Therefore, we exclude the involvement of the Src or JAK/Stat 
pathway in regulating cytoplasmic accumulation of La during TGF-β induced stress and the 
increase of LamB1 IRES translation. Our data rather indicate that MAPK/ERK signaling 
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regulates the immediate translocation of La upon TGF-β stimulation. It remains to be clarified 
whether PDGF is generally involved in regulating La translocation via MAPK/ERK during 
cellular stress or whether it is a TGF-β mediated effect. Cellular stress associating with a 
switch to PDGF-Rα signaling and IRES mediated translation is activated in this context, 
suggesting that PDGF signaling could be involved in the regulation of further ITAFs in 
addition to La. This opens the question whether other ITAFs are regulated upon EMT and 
possibly contribute to the enhanced IRES translation of LamB1.  
 The significance of these findings is underlined by recent findings demonstrating that 
cytoplasmic La contributes to the translation of oncogenes. Aberrant regulation of La has 
been particularly described in chronic myeloid leukaemia, where BCR/ABL mediated 
activation of La supports tumorigenesis [45, 46]. Phosphorylation dependent shuttling of La 
and translational activation of target genes that include tumor promoting factors was found in 
glioma cells [37]. However, La modulates translation in diverse ways including binding to the 
3’-UTR or to the cap of oligopyrimidine containing mRNAs depending on the phosphorylation 
status [37, 47]. Cytoplasmic La in EMT transformed cells might therefore affect translation of 
target genes on multiple levels. So far, La mediated modulation of IRES translation during 
apoptosis and cell cycle progression has only been described for XIAP, BIP and Cyclin D1 
[32, 38, 39]. Truncation as well as phosphorylation were found to trigger the cytoplasmic 
translocation of La during apoptosis or cellular stress, suggesting that multiple signaling 
events are involved in regulating subcellular La distribution [35, 40, 41]. Recently, Brenet et. 
al. published a PDGF-B induced, AKT dependent phosphorylation of La. In contrast to these 
findings, PDGF induced translocation of La rather depends on the MAPK/ERK pathway 
during hepatocellular EMT.  
 LamB1 signaling includes binding to LamR and β1 integrin receptors, which were 
both found to be overexpressed in HCC [21, 22]. Rearrangement of integrin receptor 
allocation and abundance is an essential step during EMT that leads to enhanced cell motility 
and survival [9, 14, 48]. Consistently, LamB1 was found to be involved in the regulation of 
cell migration suggesting that increased IRES translation of LamB1 during EMT may 
contribute to tumor cell migration and metastasis [18, 49]. Furthermore, EMT is associated 
with the activation of cell programs that regulate dedifferentiation during embryogenesis and 
has been suggested to be involved in the generation of tumor stem cells [8, 50]. Interestingly, 
LamB1 is the first laminin subunit to be expressed during early embryogenesis and is 
essentially involved in cell differentiation [51]. While embryonic cells expressing LamB1 alone 
have a mesenchymal phenotype, additional activation of Laminin α expression during E4 
stage induces epithelial cell polarization via α6β1 integrin signaling. Accordingly, a recent 
publication reported the cultivation of embryonic stem cells on laminin 10, which contains the 
LamB1 subunit, without the need of feeder cells [52]. These data indicate that the context of 
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laminin expression might be important for the generation of stem cell niches. Finally, Laminin 
1 as well as LamB1 peptides were found to regulate tube formation and sprouting during 
tumor vascularization [53, 54]. Angiogenesis is induced by hypoxic conditions and is driven 
by the increased IRES translation of VEGF-A, PDGF and bFGF mRNAs in response to 
HIF1α activation [55, 56]. Thus, it is promising to investigate the involvement of IRES driven 
LamB1 translation during tumor angiogenesis and metastasis. 
. 
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9.8. Figures 
 
 
Figure 1. LamB1 IRES translation is enhanced by La during EMT. (A) Expression of shRNA 
against La (sh84, sh87) resulted in a stable knock-down of La in epithelial MIM-R (R) and 
fibroblastoid MIM-RT (RT) cells. Non-target shRNA (shNT) was used as control. Protein lev-
els of La and LamB1 were detected by Western blotting and were quantified. The protein 
levels of MIM-R cells were set to a value of 1 for normalization. (B) qPCR of LamB1 mRNA 
levels in MIM-R and MIM-RT cells. (C) Cytoplasmic fractions of MIM-R and MIM-RT cells as 
well as MIM-R cells treated for 24 hours with 2,5 ng/ml TGF-β were analyzed by Western 
blotting and protein levels were quantified. The protein levels of MIM-R cells were set to a 
value of 1 for normalization (D) EMT of epithelial MIM-R cells was induced by administration 
of 2,5 ng/ml TGF-β in intervals of 24 hours. Cells were transfected with the bicistronic vector 
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containing the LamB1 5’-UTR between the β-gal and CAT reporter. β-gal and CAT activities 
were detected 48 hours after transfection and normalized to mRNA levels as quantified by 
qPCR. Relative reporter activities of MIM-R cells were set to a value of 1 for normalization 
(E) Total protein or (F) phospho-protein levels were detected by Western blotting and were 
quantified. The protein levels of MIM-R cells were set to a value of 1 for normalization 
***P<0.005. 
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Figure 2. The EMT-induced cytoplasmic accumulation of La is regulated by PDGF. Epithelial 
MIM-R and mesenchymal MIM-RT hepatocytes and those expressing dominant negative 
PDGF-Rα (dnP) were employed to study the subcellular localization of La. All cells were 
treated with 20 µM TGF-β inhibitor or stimulated with 10 ng/ml PDGF for 32 hours in the 
presence of 20 µM TGF-β inhibitor. (A) Cytoplasmic (c) and nuclear fractions (n) were ana-
lyzed by Western blotting. The purity of subcellular fractions was assessed by detection of 
tubulin (c) and nucleoporin (n). (B) Immunocytochemical staining of La. Arrows indicate cyto-
plasmic localization of La. (C) The effect of impaired PDGF signaling on LamB1 IRES activity 
was analyzed with a bicistronic reporter assay. Cells were transfected with a bicistronic vec-
tor containing the LamB1 5’-UTR. β-gal and CAT activities were detected 48 hours after 
transfection. Relative reporter activities of MIM-RT cells treated with TGF-β inhibitor were set 
to a value of 1 for normalization *P<0.05  
  
Dissertation                                                                                                Michaela Petz 
 124   
   
 
Figure 3. PDGF activates PI3K and MAPK signaling in EMT-transformed cells. MIM-R and 
MIM-RT cells or those expressing dnP were employed to analyze PDGF induced signaling 
by Western blotting. MIM-R and MIM-RdnP cells were treated with 2,5 ng/ml TGF-β for 24 
hours (RdnP, R) or persistently cultured with 1 ng/ml TGF-β (RTdnP, RT) to analyze TGF-β 
signaling. Cells were cultured with 20 µM TGF-β inhibitor and simultaneously treated with 10 
ng/ml PDGF for 32 hours to study PDGF signaling. 
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Figure 4. LamB1 IRES translation is enhanced by PDGF driven MAPK signaling. Hepato-
cytes expressing S35-V12-Ras undergo EMT in response to TGF-β (MIM-ST) whereas cells 
expressing C40-V12-Ras acquire a scattering phenotype (MIM-CT). All cells were treated 
with 20 µM TGF-β inhibitor or stimulated with 10 ng/ml PDGF for 32 hours in the presence of 
20 µM TGF-β inhibitor. (A) Western blot analysis of cells in response to PDGF. (B) Cells 
were transfected with a bicistronic vector containing the LamB1 5’-UTR to analyze LamB1 
IRES activity. β-gal and CAT reporter activities were measured 48 hours post transfection. 
Relative reporter activities of MIM-RT cells treated with TGF-β inhibitor were set to a value of 
1 for normalization (C) The subcellular localization of La was analyzed by Western blotting of 
cytoplasmic (c) and nuclear (n) fractions. Tubulin and nucleoporin served as cytoplasmic or 
nuclear marker, respectively. *P<0.05. 
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Figure 5. Cytoplasmic accumulation of La depends on the cooperation of MAPK and PI3K 
signaling. MIM-RT cells were treated with 10 µM of PI3K (LY) and/or MAPK (UO) inhibitor. 
DMSO was used as control. (A) Western blotting of cytoplasmic (c) and nuclear (n) fractions 
to analyze subcellular localization of La. (B) Cells were transfected with the bicistronic vector 
containing the LamB1 5’-UTR to study LamB1 IRES activity. CAT reporter activities were 
measured 48 hours after transfection and normalized to mRNA levels as quantified by qPCR. 
Relative reporter activities of MIM-RT cells treated with DMSO were set to a value of 1 for 
normalization (C) MIM-RT cells were co-transfected with a vector expressing 2A protease 
(2Awt) or an inactive mutant (2Amut) together with either a plasmid containing the LamB1 5’-
UTR in front of a Firefly luciferase reporter or the empty Firefly luciferase reporter as control. 
Relative reporter activities of MIM-RT cells that where co-transfected with the 2Amut and 
Firefly luciferase control vector were set to a value of 1 for normalization *P<0.05. 
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Figure 6. Stable knock-down of La reduces LamB1 expression and impairs tumor formation 
of EMT-transformed hepatocytes. Epithelial (MIM-R, R) or mesenchymal (MIM-RT, RT) 
hepatocytes expressing dnP or a stable knock-down of La (sh84, sh87) or the non-target 
control (shNT) were subcutaneously injected into SCID mice. (A) Mean weight of 
subcutaneous MIM-RT tumors after 16 days of growth in SCID mice. (B) Western blot 
analysis of MIM-RT-derived tumor tissue. (C) Western blotting of cytoplasmic (c) and nuclear 
(n) fractions isolated from tumor tissue. (D) Histological stainings of subcutaneous tumors. 
Insets show stainings at higher magnification. *P<0.05 or ***P<0.005.  
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Supplementary Data 
Supplementary Table S1. Primer for quantitative RT-PCR. 
description forward reverse 
β-gal reporter actatcccgaccgccttact ctgtagcgctgatgttgaa 
CAT reporter gcgtgttacggtgaaaacct gggcgaagaacttgtccata 
RhoA ggaagaaactggtgattgttggtg tcgtggttggcttctaaatactgg 
murine LamB1 caggaaccggagttcagcta gcaggtggctaacaatacag 
 
 
Supplementary Figure S1. Western blot analysis as quantified and shown in Figure 1E and 
1F. (A) EMT was induced in MIM-R cells by treatment with 2,5 ng/ml TGF-β for 120 hours. 
Cells were passaged every 24 hours and supplied with TGF-β. (B) Western blot analysis of 
immortalized (MIM-1-4), Ras-transformed (MIM-R) and EMT-transformed (MIM-RT) 
hepatocytes. (C) Western blot analysis of MIM-R (R) and MIM-RT (RT) cells or MIM-R cells 
stimulated with 2,5 ng/ml TGF-β for 24 hours (R+TGF-β). (D) Quantification of phospho-eIFs 
levels that are shown in Supplementary Figure 1A. 
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Supplementary Figure S2. Immunocytochemical stainings for La. EMT- transformed cells 
that preferentially activate MAPK/ERK (MIM-ST) or PI3K/AKT (MIM-CT) signaling in 
response to cognate signals were cultured with 1 ng/ml TGF-β, treated with TGF-β inhibitor 
or co-treated with TGF-β inhibitor and PDGF for 32 hours. Cells were fixed on collagen 
coated glass slides and stained for La. Arrows indicate cytoplasmic localization of La.  
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Supplementary Figure S3. Mesenchymal MIM-RT (control) hepatocytes or those MIM-RT 
cells expressing a stable knock-down of La (shLa84, shLa87) or the non-target control 
(shNT) or dnP were subcutaneously injected into SCID mice. Tumor length and width were 
measured every two days and the tumor volume was calculated by the formula (length x 
width2) x ½.  
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